

PA-0046 US

GENES REGULATED BY MYCN ACTIVATION

This application claims benefit of provisional application Serial No. 60/270,784, filed 23 February 2001.

5

FIELD OF THE INVENTION

The present invention relates to a combination comprising a plurality of cDNAs which are differentially expressed in response to MYCN activation and which may be used entirely or in part to diagnose, to stage, to treat, or to monitor the progression or treatment of disorders associated with MYCN activation such as neuroblastoma and other cancers.

10

BACKGROUND OF THE INVENTION

MYCN functions as a transactivator by forming a heterodimer with a helix-loop-helix (HLH)-leucine zipper protein, MAX, and binding to a core E-box promoter element, CAT/cGTG. Although MYCC, MYCN and MYCL can all bind to the canonical core element, promoter-flanking sequences can markedly affect binding affinities of the different MYC isoforms to individual target genes (Prochownik *et al.* (1993) Proc Natl Acad Sci 90:960-964). In addition, other regulatory molecules that influence both the activity of MYC and the interaction of MYC with MAX contribute to the tissue specificity of MYCN and MYCC oncogene transactivation (O'Hagan *et al.* (2000) Nat Genet 24:113-9; and Hurlin *et al.* (1996) Embo J 15:2030).

20 The MYCN proto-oncogene is amplified in approximately 30% of neuroblastoma and 20-25% of small cell lung cancers. Amplification of MYCN is the most reliable negative prognostic factor in neuroblastoma (Bordow *et al.* (1998) J Clin Oncol 16:3286-94). Three-year survival for patients with metastatic neuroblastoma decreases from approximately 40% to less than 10% with MYCN amplification (Matthay *et al.* (1999) N Engl J Med 341:1165-73). Despite intensive efforts, MYCN transcriptional targets responsible for the particularly malignant phenotype of these tumors have remained elusive (Nesbit *et al.* (1999) Oncogene 18:3004-16).

25 Minichromosome maintenance (MCM) molecules are a highly conserved group of DNA binding proteins with a vital function of "licensing" DNA synthesis during the transition from G1 to S phase of the cell cycle (Takisawa *et al.* (2000) Curr Opin Cell Biol 12:690-696). Originally characterized in yeast, the MCM group of proteins is required for activation of autonomous replicating sequences and progression through the cell division cycle. In eukaryotes, MCM2 to MCM7 are sequentially assembled into a heteromeric hexamer, 30 the replication licensing factor (RLF), that binds to DNA replication origins after the origin recognition complex (ORC) has assembled at the end of G1 (Maiorano *et al.* (2000) J Biol Chem 275:8426-31; for review, see Kearsey and Labib (1998) Biochim Biophys Acta 1398:113-36; Tye (1999) Annu Rev Biochem 68:649-86; and Thommes and Blow (1997) Cancer Surv 29:75-90). MCM-mediated regulation of DNA synthesis ensures that DNA replicates only once during each cell cycle and is essential for maintaining euploidy.

PA-0046 US

Immunohistochemical studies in a variety of tissues demonstrate increased expression of MCM2, 5, and 7 in solid tumors and pre-malignant proliferative states (Todorov *et al.* (1998) Lab Invest 78:73-8; Freeman *et al.* (1999) Clin Cancer Res 5:2121-32; and Hiraiwa *et al.* (1998) J Cutan Pathol 25:285-90). Their vital role in the maintenance of chromosomal integrity in normal cells makes the MCM molecules potential targets of the transforming effects of cellular oncogenes. The promoter regions of MCM5, 6 and 7 each contain numerous E2F transactivation sites, suggesting that the E2F transcription factor may be primarily responsible for the coordinated increase in MCM mRNA noted at the G1/S boundary (Ohtani *et al.* (1999) Oncogene 18, 2299-309; Suzuki *et al.* (1998) Gene 216:85-91). However, in addition to the E2F sites, the MCM7 promoter has an E-box binding site for the MYC oncogene (Suzuki, *supra*).

10 Array technology can provide a simple way to explore the expression profile of a large number of related or unrelated genes. The potential application of gene expression profiling is particularly relevant to improving diagnosis, prognosis, and treatment of disease. For example, both the levels and sequences expressed in tissues from subjects with neuroblastoma associated with MYCN amplification may be compared with the levels and sequences expressed in neuroblastoma without MYCN amplification.

15 The present invention provides a combination comprising a plurality of cDNAs for use in detecting changes in expression of genes encoding proteins that are associated with MYCN activation. Such a combination satisfies a need in the art by providing a combination of cDNAs that represent a set of differentially expressed genes which may be used entirely or in part to diagnose, to stage, to treat, or to monitor the progression or treatment of disorders such as neuroblastoma and other cancers.

20 **SUMMARY**

The present invention provides a combination comprising a plurality of cDNAs and their complements which are differentially expressed by MYCN activation and which are selected from SEQ ID NOS:1-365 as presented in the Sequence Listing. In one embodiment, each cDNA is downregulated at least two-fold, SEQ ID NOS:1-280; in another embodiment, each cDNA is upregulated at least two-fold, SEQ ID NOS:281-365. 25 In one aspect, the combination is useful to diagnose, to stage, to treat, or to monitor the progression or treatment of disorders associated with MYCN activation such as neuroblastoma and other cancers. In another aspect, the combination is immobilized on a substrate.

The invention also provides a high throughput method to detect differential expression of one or more of the cDNAs of the combination. The method comprises hybridizing the substrate containing the combination with nucleic acids of a sample, thereby forming one or more hybridization complexes, detecting complex formation, and comparing complexes with those of a standard, wherein differences in the size and signal intensity of each complex indicates differential expression of nucleic acids in the sample. In one aspect, the sample is from a subject with neuroblastoma and differential expression determines an early, mid, and late

PA-0046 US

stage of that disorder.

The invention further provides a high throughput method for screening a library or a plurality of molecules or compounds to identify a ligand. The method comprises combining the substrate comprising the combination of cDNAs with a library or a plurality of molecules or compounds under conditions to allow specific binding and detecting specific binding, thereby identifying a ligand which specifically binds at least one cDNA of the combination. The library or plurality of molecules or compounds are selected from DNA molecules, RNA molecules, peptide nucleic acid molecules, mimetics, peptides, transcription factors, repressors, and other regulatory proteins. The invention additionally provides a method for purifying a ligand, the method comprising combining a cDNA of the invention with a sample under conditions which allow specific binding, recovering the bound cDNA, and separating the cDNA from the ligand, thereby obtaining purified ligand.

The invention provides an isolated cDNA selected from SEQ ID NOS:1-365. The invention also provides a vector comprising the cDNA, a host cell comprising the vector, and a method for producing a protein comprising culturing the host cell under conditions for the expression of a protein and recovering the protein from the host cell culture. The invention further provides a method to detect differential expression of a cDNAs of the combination. The method comprises using a cDNA of the invention to detect expression of nucleic acids in a sample comprising contacting the cDNA with the sample, thereby forming a hybridization complex, detecting complex formation wherein complex formation indicates expression of the nucleic acid in the sample. In one aspect, the sample is from a subject with neuroblastoma and differential expression of the cDNA determines the stage of the disorder.

The invention provides a method for using a cDNA to screen a library or a plurality of molecules or compounds to identify a ligand. The method comprises combining the cDNA with a library or a plurality of molecules or compounds under conditions to allow specific binding and detecting specific binding, thereby identifying a ligand which specifically binds the cDNA. The library or plurality of molecules or compounds are selected from DNA molecules, RNA molecules, peptide nucleic acid molecules, mimetics, peptides, transcription factors, repressors, and other regulatory proteins. The invention additionally provides a method for purifying a ligand such as a transcription factor, the method comprising combining the cDNA with a sample under conditions which allow specific binding, recovering the bound cDNA, and separating the cDNA from the ligand, thereby obtaining purified ligand.

The present invention provides a purified protein encoded and produced by a cDNA of the invention. The invention also provides a high-throughput method for using a protein to screen a library or a plurality of molecules or compounds to identify a ligand. The method comprises combining the protein or a portion

PA-0046 US

thereof with the library or plurality of molecules or compounds under conditions to allow specific binding and detecting specific binding, thereby identifying a ligand which specifically binds the protein. The library or plurality of molecules or compounds is selected from DNA molecules, RNA molecules, peptide nucleic acid molecules, mimetics, peptides, proteins, agonists, antagonists, antibodies or their fragments, immunoglobulins, inhibitors, drug compounds, and pharmaceutical agents.

The invention provides a method for using a protein to produce and purify an antibody, the method comprising immunizing an animal with the protein under conditions to elicit an antibody response; isolating animal antibodies; contacting the protein with the isolated antibodies under conditions to allow specific binding; recovering the bound protein; and separating the protein from the antibody, thereby obtaining purified antibody. The invention also provides a method for using an antibody to detect expression of a protein in a sample, the method comprising contacting the antibody with a sample under condition for the formation of an antibody:protein complex; and detecting the antibody:protein complex wherein complex formation indicates the expression of the protein in the sample. In one aspect, complex formation is compared to standards and is diagnostic of cancer, particularly a neuroblastoma. The invention further provides a method of using an antibody to immunopurify a protein comprising combining the antibody with a sample under conditions to allow formation of an antibody:protein complex, and separating the antibody from the protein, thereby obtaining purified protein.

The invention further provides a composition comprising a cDNA, a protein, an antibody, or a ligand which has agonistic or antagonistic activity.

20

DESCRIPTION OF THE COMPACT DISC-RECORDABLE (CD-R)

CD-R 1 is labeled: "PA-0046 US, Copy 1," was created on 02/25/2002 and contains: the Sequence Listing formatted in plain ASCII text. The file for the Sequence Listing is entitled pa46sqls.txt, created on 02/25/2002 and is 1360 KB in size.

CD-R 2 is an exact copy of CD-R 1. CD-R 2 is labeled: "PA-0046 US, Copy 2," and was created on 02/25/2002.

The CD-R labeled as: "PA-0046 US, CRF," contains the Sequence Listing formatted in plain ASCII text. The file for the Sequence Listing is entitled pa46sqsl.txt, was created on 02/25/2002 and is 1360 KB in size.

The content of the Sequence Listing named above and as described below, submitted in duplicate on two (2) CD-Rs (labeled "PA-0046 US, Copy 1" and "PA-0046 US, Copy 2"), and the CRF (labeled "PA-0046

PA-0046 US

US, CRF") containing the Sequence Listing, are incorporated by reference herein, in their entirety.

DESCRIPTION OF THE SEQUENCE LISTING AND TABLES

A portion of the disclosure of this patent document contains material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent 5 document or the patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever.

The Sequence Listing is a compilation of cDNAs obtained by sequencing and extending clone inserts. Each sequence is identified by a sequence identification number (SEQ ID NO) and by the template number (INCYTE ID) from which it was obtained.

10 Table 1 lists the functional annotation and differential expression of the cDNAs of the present invention. Columns 1, 2 and 3 show the SEQ ID NO, TEMPLATE ID, and CLONE ID, respectively. Columns 4, 5 and 6 show the GenBank hit (GENBANK HIT), probability score (E-VALUE), and functional annotation (ANNOTATION), respectively, as determined by BLAST analysis (version 1.4 using default parameters; Altschul (1993) J Mol Evol 36: 290-300; Altschul *et al.* (1990) J Mol Biol 215:403-410) of the 15 cDNA against GenBank (release 121; National Center for Biotechnology Information (NCBI; Bethesda MD). Column 7 shows the balanced differential expression (BAL DE) of each cDNA. Downregulation is represented by positive values and is calculated as the ratio of expression in non-activated cells relative to MYCN activated cells. Upregulation is represented by negative values and is calculated as the ratio of expression in MYCN activated cells relative to non-activated cells.

20 Table 2 shows the region of each cDNA encompassed by the clone present on a microarray and identified as differentially expressed. Columns 1 and 2 show the SEQ ID NO and TEMPLATE ID, respectively. Column 3 shows the CLONE ID and columns 4 and 5 show the first residue (START) and last residue (STOP) encompassed by the clone on the template.

DESCRIPTION OF THE INVENTION**25 Definitions**

"Antibody" refers to intact immunoglobulin molecule, a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a recombinant antibody, a humanized antibody, single chain antibodies, a Fab fragment, an F(ab')₂ fragment, an Fv fragment; and an antibody-peptide fusion protein.

30 "Antigenic determinant" refers to an immunogenic epitope, structural feature, or region of an oligopeptide, peptide, or protein which is capable of inducing formation of an antibody which specifically binds the protein. Biological activity is not a prerequisite for immunogenicity.

"Array" refers to an ordered arrangement of at least two cDNAs, proteins, or antibodies on a substrate. At least one of the cDNAs, proteins, or antibodies represents a control or standard, and the other

PA-0046 US

cDNA, protein, or antibody is of diagnostic or therapeutic interest. The arrangement of two to about 40,000 cDNAs, proteins, or antibodies on the substrate assures that the size and signal intensity of each labeled complex, formed between each cDNA and at least one nucleic acid, each protein and at least one ligand or antibody, or each antibody and at least one protein to which the antibody specifically binds, is individually
 5 distinguishable.

"Cancer" refers to adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers or tumors of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, colon, esophagus, gall bladder, ganglia, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, small intestine, spleen, stomach, testis, thymus, thyroid, and
 10 uterus.

A "combination" comprises at least two and up to about 730 sequences selected from SEQ ID NOs:1-365 as presented in the Sequence Listing and the complements thereof.

The "complement" of a nucleic acid of the Sequence Listing refers to a nucleotide sequence which is completely complementary over the full length of the sequence and which will hybridize to the nucleic acid
 15 under conditions of high stringency.

"cDNA" refers to a chain of from about 400 to about 12000 nucleotides, an isolated polynucleotide, nucleic acid, or any fragment thereof. It may have originated recombinantly or synthetically, be double-stranded or single-stranded, coding and/or noncoding, an exon with or without an intron, and purified or combined with carbohydrate, lipids, protein or inorganic elements or substances.

The "complement" of a nucleic acid of the Sequence Listing refers to a nucleotide sequence which is completely complementary over the full length of the sequence and which will hybridize to the nucleic acid under conditions of high stringency.

The phrase "cDNA encoding a protein" refers to a nucleic acid sequence that closely aligns with sequences which encode conserved regions, motifs or domains that were identified by employing analyses well known in the art. These analyses include BLAST (Basic Local Alignment Search Tool; Altschul (1993) supra; Altschul (1990) supra) which provides identity within the conserved region. Brenner *et al.* (1998; Proc Natl Acad Sci 95:6073-6078) who analyzed BLAST for its ability to identify structural homologs by sequence identity found 30% identity is a reliable threshold for sequence alignments of at least 150 residues and 40% is a reasonable threshold for alignments of at least 70 residues (Brenner, page 6076, column 2).

"Derivative" refers to a cDNA or a protein that has been subjected to a chemical modification. Derivatization of a cDNA can involve substitution of a nontraditional base such as queosine or of an analog such as hypoxanthine. These substitutions are well known in the art. Derivatization of a protein involves the

PA-0046 US

replacement of a hydrogen by an acetyl, acyl, alkyl, amino, formyl, or morpholino group. Derivative molecules retain the biological activities of the naturally occurring molecules but may confer longer lifespan or enhanced activity.

"Differential expression" refers to an increased or upregulated or a decreased or downregulated expression as detected by presence, absence or at least two-fold change in the amount or abundance of a transcribed messenger RNA or translated protein in a sample.

"Disorder" refers to conditions, diseases or syndromes associated with MYCN activation, defined by amplification of MYCN gene expression, and includes neuroblastoma and other cancers.

"Fragment" refers to a chain of consecutive nucleotides from about 200 to about 700 base pairs in length. Fragments may be used in PCR or hybridization technologies to identify related nucleic acids and in binding assays to screen for a ligand. Nucleic acids and their ligands identified in this manner are useful as therapeutics to regulate replication, transcription or translation.

An "expression profile" is a representation of gene expression in a sample. A nucleic acid expression profile is produced using sequencing, hybridization, or amplification technologies and mRNAs or cDNAs from a sample. A protein expression profile, although time delayed, mirrors the nucleic acid expression profile and uses labeling moieties or antibodies to detect expression in a sample. The nucleic acids, proteins, or antibodies may be used in solution or attached to a substrate, and their detection is based on methods well known in the art.

A "hybridization complex" is formed between a cDNA and a nucleic acid of a sample when the purines of one molecule hydrogen bond with the pyrimidines of the complementary molecule, e.g., 5'-A-G-T-C-3' base pairs with 3'-T-C-A-G-5'. The degree of complementarity and the use of nucleotide analogs affect the efficiency and stringency of hybridization reactions.

"Identity" as applied to nucleic acid or protein sequences, refers to the quantification (usually percentage) of nucleotide or residue matches between at least two sequences aligned using a standardized algorithm such as Smith-Waterman alignment (Smith and Waterman (1981) J Mol Biol 147:195-197), CLUSTALW (Thompson *et al.* (1994) Nucleic Acids Res 22:4673-4680), or BLAST2 (Altschul *et al.* (1997) Nucleic Acids Res 25:3389-3402). BLAST2 may be used in a standardized and reproducible way to insert gaps in one of the sequences in order to optimize alignment and to achieve a more meaningful comparison between them. Similarity is an analogous score, but it is calculated with conservative substitutions taken into account; for example, substitution of a valine for an isoleucine or leucine.

"Isolated or purified" refers to a cDNA, protein, or antibody that is removed from its natural environment or from cell culture and that is separated from other components with which it is associated.

PA-0046 US

"Labeling moiety" refers to any reporter molecule whether a visible or radioactive label, stain or dye that can be attached to or incorporated into a cDNA or protein. Visible labels and dyes include but are not limited to anthocyanins, β glucuronidase, BIODIPY, Coomassie blue, Cy3 and Cy5, digoxigenin, FITC, green fluorescent protein (GFP), luciferase, spyro red, silver, and the like. Radioactive markers include radioactive forms of hydrogen, iodine, phosphorous, sulfur, and the like.

"Ligand" refers to any agent, molecule, or compound which will bind specifically to a complementary site on a polynucleotide, protein, or antibody of the invention. Such ligands stabilize, modulate, or disrupt the activity of polynucleotides, proteins, or antibodies and may be composed of inorganic and/or organic substances including minerals, cofactors, nucleic acids, proteins, carbohydrates, fats, and lipids.

"Oligonucleotide" refers a single stranded molecule from about 18 to about 60 nucleotides in length which may be used in hybridization or amplification technologies or in regulation of replication, transcription or translation. Equivalent terms are amplimer, primer, and oligomer.

"Post-translational modification" of a protein can involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and the like. These processes may occur synthetically or 15 biochemically. Biochemical modifications will vary by cellular location, cell type, pH, enzymatic milieu, and the like.

"Probe" refers to a cDNA that hybridizes to at least one nucleic acid in a sample. Where targets are single stranded, probes are complementary single strands. Probes can be labeled for use in hybridization reactions including Southern, northern, in situ, dot blot, array, and like technologies.

"Protein" refers to a polypeptide or any portion thereof. A "portion" of a protein refers to that length of amino acid sequence which would retain at least one biological activity, a domain identified by PFAM or PRINTS analysis or an antigenic determinant of the protein identified using Kyte-Doolittle algorithms of the PROTEAN program (DNASTAR, Madison WI). An "oligopeptide" is an amino acid sequence from about five residues to about 15 residues that is used as part of a fusion protein to produce an antibody.

"Sample" is used in its broadest sense as containing nucleic acids, proteins, antibodies, and the like. A sample may comprise a bodily fluid; the soluble fraction of a cell preparation, or an aliquot of media in which cells were grown; a chromosome, an organelle, or membrane isolated or extracted from a cell; genomic DNA, RNA, or cDNA in solution or bound to a substrate; a cell; a tissue or tissue biopsy; a tissue print; buccal cells, skin, a hair or hair follicle; and the like.

"Specific binding" refers to a special and precise interaction between two molecules which is dependent upon their structure, particularly their molecular side groups. For example, the intercalation of a regulatory protein into the major groove of a DNA molecule, the hydrogen bonding along the backbone

PA-0046 US

between two single stranded nucleic acids, or the binding between an antigenic determinant of a protein and an agonist, antagonist, or antibody.

"Substrate" refers to any rigid or semi-rigid support to which cDNAs, proteins, or antibodies are bound and includes membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, capillaries or other tubing, plates, polymers, and microparticles with a variety of surface forms including wells, trenches, pins, channels and pores.

A "transcript image" (TI) is a profile of gene transcription activity in a particular tissue at a particular time. TI provides assessment of the relative abundance of expressed polynucleotides in the cDNA libraries of an EST database as described in USPN 5,840,484, incorporated herein by reference.

"Variant" refers to molecules that are recognized variations of a cDNA or a protein encoded by the cDNA. Splice variants may be determined by BLAST score, wherein the score is at least 100, and most preferably at least 400. Allelic variants have a high percent identity to the cDNAs and may differ by about three bases per hundred bases. "Single nucleotide polymorphism" (SNP) refers to a change in a single base as a result of a substitution, insertion or deletion. The change may be conservative (purine for purine) or non-conservative (purine to pyrimidine) and may or may not result in a change in an encoded amino acid.

The Invention

The present invention provides for a combination comprising a plurality of cDNAs or their complements, SEQ ID NOs:1-365 which may be used to diagnose, to stage, to treat or to monitor the progression or treatment of a disorder associated with MYCN activation. MYCN activation occurs upon amplification of MYCN gene expression. The cDNAs of the invention represent known and novel genes differentially expressed between a tumor explant from an INSS stage 4 neuroblastoma patient showing amplified MYCN (P4) and a tumor explant from an INSS stage 4 neuroblastoma patient showing non-amplified MYCN (P67). The combination may be used in its entirety or in part, as subsets of downregulated cDNAs, SEQ ID NOs:1-280, or of upregulated cDNAs, SEQ ID NOs:280-365. Since the cDNAs were identified solely by their differential expression, it is not essential to know *a priori* the name, structure, or function of the gene or its encoded protein. The usefulness of the cDNAs exists in their immediate value as diagnostics for disorders associated with MYCN activation such as neuroblastoma.

Table 1 shows those genes on the array having differential expression (4-fold or greater increase or decrease) in the MYCN amplified neuroblastoma. Columns 1, 2, and 3 show the SEQ ID NO, Template ID, and Clone ID, respectively. Columns 4, 5, and 6 show the GenBank Hit ID, the probability score (E-value) for the hit relative to the template or its encoded protein, and a relevant description (annotation). Column 7 shows the balanced differential expression (BAL DE) of each cDNA. Positive values represent a

PA-0046 US

comparison of expression level in non-activated cells relative to MYCN activated cells (downregulation). Negative values represent a comparison of expression level in MYCN activated cells relative to non-activated cells (upregulation). Table 2 shows the region of each cDNA encompassed by the clone present on a microarray and identified as differentially expressed. Columns 1 and 2 show the SEQ ID NO and 5 TEMPLATE ID, respectively. Column 3 shows the CLONE ID and columns 4 and 5 show the first residue (START) and last residue (STOP) encompassed by the clone on the template.

Regulation of the cDNAs of the invention by MYCN amplification were verified using SEQ ID NO:354, which is upregulated 9.9-fold in the MYCN amplified (P4) tumor relative to non-amplified (P67) tumor (Table 1). Immunohistochemistry on tissue sections from several MYCN amplified and non-amplified 10 INSS stage 4 neuroblastoma tumors with an anti-MCM7 mAb showed the majority of tumor cells in the MYCN amplified samples stained positive with a well-defined nuclear staining pattern. By contrast, only scattered foci of positive staining were demonstrated in the MYCN non-amplified samples despite the fact that the overall proliferative fractions of the tumor samples were very similar. Hematoxylin and eosin staining and neuron-specific enolase staining demonstrated no gross histological differences between the amplified and 15 non-amplified specimens tested. Western blot analysis demonstrated a three fold increase in MCM7 protein upon induction of MYCN in a MYCN conditional neuroblastoma cell line. MCM7 upregulation was also confirmed by RT-PCR in a MYCN non-amplified neuroblastoma cell line, SH-EP, stably transfected with the MYCN gene under the control of the rTet inducible expression system wherein MYCN expression is induced upon removal of tetracycline. Phenotypic changes observed upon MYCN induction in this cell line, TET-21, 20 have been well characterized and include cell cycle alterations, increased proliferation rate and increased metastatic potential (Lutz *et al.* (1996) Oncogene 13:803-12). Up-regulation of MCM7 transcription was maximal in the TET21 cell line 6 h after removal of tetracycline. The protein level of MCM7 also increased 3-fold as determined by quantitative western blots.

The cDNAs of the invention define a differential expression pattern against which to compare the 25 expression pattern of biopsied and/or *in vitro* treated neuroblastoma tissues. Experimentally, differential expression of the cDNAs can be evaluated by other methods including, but not limited to, differential display by spatial immobilization or by gel electrophoresis, genome mismatch scanning, representational discriminant analysis, clustering, transcript imaging and other array technologies. These methods may be used alone or in combination to verify the differential expression patterns that characterize a particular tissue, disorder, or 30 therapy.

The combination may be arranged on a substrate and hybridized with tissues from subjects with diagnosed neuroblastoma to identify those sequences which are differentially expressed in both neuroblastoma

PA-0046 US

and other phenotypically similar disorders. This allows identification of those sequences of highest diagnostic and potential therapeutic value. In one embodiment, an additional set of cDNAs, such as cDNAs encoding signaling molecules, are arranged on the substrate with the combination. Such combinations may be useful in the elucidation of pathways which are affected in a particular disorder or to identify new, coexpressed, 5 candidate, therapeutic molecules.

In another embodiment, the combination can be used for large scale genetic or gene expression analysis of a large number of novel, nucleic acids. These samples are prepared by methods well known in the art and are from mammalian cells or tissues which are in a certain stage of development; have been treated with a known molecule or compound, such as a cytokine, growth factor, a drug, and the like; or have been 10 extracted or biopsied from a mammal with a known or unknown condition, disorder, or disease before or after treatment. The sample nucleic acids are hybridized to the combination for the purpose of defining a novel gene profile associated with that developmental stage, treatment, or disorder.

cDNAs and Their Uses

cDNAs can be prepared by a variety of synthetic or enzymatic methods well known in the art. 15 cDNAs can be synthesized, entirely or in part, using chemical methods well known in the art (Caruthers *et al.* (1980) Nucleic Acids Symp Ser (7):215-233). Alternatively, cDNAs can be produced enzymatically or recombinantly, by *in vitro* or *in vivo* transcription.

Nucleotide analogs can be incorporated into cDNAs by methods well known in the art. The only requirement is that the incorporated analog must base pair with native purines or pyrimidines. For example, 2, 20 6-diaminopurine can substitute for adenine and form stronger bonds with thymidine than those between adenine and thymidine. A weaker pair is formed when hypoxanthine is substituted for guanine and base pairs with cytosine. Additionally, cDNAs can include nucleotides that have been derivatized chemically or enzymatically.

cDNAs can be synthesized on a substrate. Synthesis on the surface of a substrate may be 25 accomplished using a chemical coupling procedure and a piezoelectric printing apparatus as described by Baldeschweiler *et al.* (PCT publication WO95/25116). Alternatively, the cDNAs can be synthesized on a substrate surface using a self-addressable electronic device that controls when reagents are added as described in USPN 5,605,662. cDNAs can be synthesized directly on a substrate by sequentially dispensing reagents for their synthesis on the substrate surface or by dispensing preformed DNA fragments to the 30 substrate surface. Typical dispensers include a micropipette delivering solution to the substrate with a robotic system to control the position of the micropipette with respect to the substrate. There can be a multiplicity of dispensers so that reagents can be delivered to the reaction regions efficiently.

PA-0046 US

cDNAs can be immobilized on a substrate by covalent means such as by chemical bonding procedures or UV irradiation. In one method, a cDNA is bound to a glass surface which has been modified to contain epoxide or aldehyde groups. In another method, a cDNA is placed on a polylysine coated surface and UV cross-linked to it as described by Shalon *et al.* (WO95/35505). In yet another method, a cDNA is actively transported from a solution to a given position on a substrate by electrical means (USPN 5,605,662). cDNAs do not have to be directly bound to the substrate, but rather can be bound to the substrate through a linker group. The linker groups are typically about 6 to 50 atoms long to provide exposure of the attached cDNA. Preferred linker groups include ethylene glycol oligomers, diamines, diacids and the like. Reactive groups on the substrate surface react with a terminal group of the linker to bind the linker to the substrate.

10 The other terminus of the linker is then bound to the cDNA. Alternatively, polynucleotides, plasmids or cells can be arranged on a filter. In the latter case, cells are lysed, proteins and cellular components degraded, and the DNA is coupled to the filter by UV cross-linking.

The cDNAs may be used for a variety of purposes. For example, the combination of the invention may be used on an array. The array, in turn, can be used in high-throughput methods for detecting a related 15 polynucleotide in a sample, screening a plurality of molecules or compounds to identify a ligand, diagnosing neuroblastoma, or inhibiting or inactivating a therapeutically relevant gene related to the cDNA.

When the cDNAs of the invention are employed on a microarray, the cDNAs are arranged in an ordered fashion so that each cDNA is present at a specified location. Because the cDNAs are at specified locations on the substrate, the hybridization patterns and intensities, which together create a unique expression 20 profile, can be interpreted in terms of expression levels of particular genes and can be correlated with a particular metabolic process, condition, disorder, disease, stage of disease, or treatment. Hybridization

The cDNAs or fragments or complements thereof may be used in various hybridization technologies. The cDNAs may be labeled using a variety of reporter molecules by either PCR, recombinant, or enzymatic techniques. For example, a commercially available vector containing the cDNA is transcribed in the presence 25 of an appropriate polymerase, such as T7 or SP6 polymerase, and at least one labeled nucleotide. Commercial kits are available for labeling and cleanup of such cDNAs. Radioactive (Amersham Pharmacia Biotech (APB), Piscataway NJ), fluorescent (Qiagen-Operon, Alameda CA), and chemiluminescent labeling (Promega, Madison WI) are well known in the art.

A cDNA may represent the complete coding region of an mRNA or be designed or derived from 30 unique regions of the mRNA or genomic molecule, an intron, a 3' untranslated region, or from a conserved motif. The cDNA is at least 18 contiguous nucleotides in length and is usually single stranded. Such a cDNA may be used under hybridization conditions that allow binding only to an identical sequence, a naturally

PA-0046 US

occurring molecule encoding the same protein, or an allelic variant. Discovery of related human and mammalian sequences may also be accomplished using a pool of degenerate cDNAs and appropriate hybridization conditions. Generally, a cDNA for use in Southern or northern hybridizations may be from about 400 to about 6000 nucleotides long. Such cDNAs have high binding specificity in solution-based or substrate-based hybridizations. An oligonucleotide, a fragment of the cDNA, may be used to detect a polynucleotide in a sample using PCR.

The stringency of hybridization is determined by G+C content of the cDNA, salt concentration, and temperature. In particular, stringency is increased by reducing the concentration of salt or raising the hybridization temperature. In solutions used for some membrane based hybridizations, addition of an organic solvent such as formamide allows the reaction to occur at a lower temperature. Hybridization may be performed with buffers, such as 5x saline sodium citrate (SSC) with 1% sodium dodecyl sulfate (SDS) at 60°C, that permit the formation of a hybridization complex between nucleic acid sequences that contain some mismatches. Subsequent washes are performed with buffers such as 0.2xSSC with 0.1% SDS at either 45°C (medium stringency) or 65°-68°C (high stringency). At high stringency, hybridization complexes will remain stable only where the nucleic acids are completely complementary. In some membrane-based hybridizations, preferably 35% or most preferably 50%, formamide may be added to the hybridization solution to reduce the temperature at which hybridization is performed. Background signals may be reduced by the use of detergents such as Sarkosyl or TRITON X-100 (Sigma-Aldrich, St. Louis MO) and a blocking agent such as denatured salmon sperm DNA. Selection of components and conditions for hybridization are well known to those skilled in the art and are reviewed in Ausubel et al. (1997, Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, Units 2.8-2.11, 3.18-3.19 and 4-6-4.9).

Dot-blot, slot-blot, low density and high density arrays are prepared and analyzed using methods known in the art. cDNAs from about 18 consecutive nucleotides to about 5000 consecutive nucleotides in length are contemplated by the invention and used in array technologies. The preferred number of cDNAs on an array is at least about 100,000, a more preferred number is at least about 40,000, an even more preferred number is at least about 10,000, and a most preferred number is at least about 600 to about 800. The array may be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and SNPs. Such information may be used to determine gene function; to understand the genetic basis of a disorder; to diagnose a disorder; and to develop and monitor the activities of therapeutic agents being used to control or cure a disorder. (See, e.g., USPN 5,474,796; WO95/11995; WO95/35505; USPN 5,605,662; and USPN 5,958,342.)

Screening and Purification Assays

PA-0046 US

A cDNA may be used to screen a library or a plurality of molecules or compounds for a ligand which specifically binds the cDNA. Ligands may be DNA molecules, RNA molecules, peptide nucleic acid molecules, peptides, proteins such as transcription factors, promoters, enhancers, repressors, and other proteins that regulate replication, transcription, or translation of the polynucleotide in the biological system.

- 5 The assay involves combining the cDNA or a fragment thereof with the molecules or compounds under conditions that allow specific binding and detecting the bound cDNA to identify at least one ligand that specifically binds the cDNA.

In one embodiment, the cDNA may be incubated with a library of isolated and purified molecules or compounds and binding activity determined by methods such as a gel-retardation assay (USPN 6,010,849) or a reticulocyte lysate transcriptional assay. In another embodiment, the cDNA may be incubated with nuclear extracts from biopsied and/or cultured cells and tissues. Specific binding between the cDNA and a molecule or compound in the nuclear extract is initially determined by gel shift assay. Protein binding may be confirmed by raising antibodies against the protein and adding the antibodies to the gel-retardation assay where specific binding will cause a supershift in the assay.

- 10 15 In another embodiment, the cDNA may be used to purify a molecule or compound using affinity chromatography methods well known in the art. In one embodiment, the cDNA is chemically reacted with cyanogen bromide groups on a polymeric resin or gel. Then a sample is passed over and reacts with or binds to the cDNA. The molecule or compound which is bound to the cDNA may be released from the cDNA by increasing the salt concentration of the flow-through medium and collected.

- 20 The cDNA may be used to purify a ligand from a sample. A method for using a cDNA to purify a ligand would involve combining the cDNA or a fragment thereof with a sample under conditions to allow specific binding, recovering the bound cDNA, and using an appropriate agent to separate the cDNA from the purified ligand.

Protein Production and Uses

- 25 The full length cDNAs or fragments thereof may be used to produce purified proteins using recombinant DNA technologies described herein and taught in Ausubel (*supra*; Units 16.1-16.62). One of the advantages of producing proteins by these procedures is the ability to obtain highly-enriched sources of the proteins thereby simplifying purification procedures.

- 30 The proteins may contain amino acid substitutions, deletions or insertions made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. Such substitutions may be conservative in nature when the substituted residue has structural or chemical properties similar to the original residue (e.g., replacement of leucine with isoleucine or

PA-0046 US

valine) or they may be nonconservative when the replacement residue is radically different (e.g., a glycine replaced by a tryptophan). Computer programs included in LASERGENE software (DNASTAR, Madison WI), MACVECTOR software (Genetics Computer Group, Madison WI) and algorithms included in RasMol software (University of Massachusetts, Amherst MA) may be used to help determine which and how many amino acid residues in a particular portion of the protein may be substituted, inserted, or deleted without abolishing biological or immunological activity.

Expression of Encoded Proteins

Expression of a particular cDNA may be accomplished by cloning the cDNA into a vector and transforming this vector into a host cell. The cloning vector used for the construction of cDNA libraries in the LIFESEQ databases (Incyte Genomics, Palo Alto CA) may also be used for expression. Such vectors usually contain a promoter and a polylinker useful for cloning, priming, and transcription. An exemplary vector may also contain the promoter for β -galactosidase, an amino-terminal methionine and the subsequent seven amino acid residues of β -galactosidase. The vector may be transformed into competent *E. coli* cells. Induction of the isolated bacterial strain with isopropylthiogalactoside (IPTG) using standard methods will produce a fusion protein that contains an N terminal methionine, the first seven residues of β -galactosidase, about 15 residues of linker, and the protein encoded by the cDNA.

The cDNA may be shuttled into other vectors known to be useful for expression of protein in specific hosts. Oligonucleotides containing cloning sites and fragments of DNA sufficient to hybridize to stretches at both ends of the cDNA may be chemically synthesized by standard methods. These primers may then be used to amplify the desired fragments by PCR. The fragments may be digested with appropriate restriction enzymes under standard conditions and isolated using gel electrophoresis. Alternatively, similar fragments are produced by digestion of the cDNA with appropriate restriction enzymes and filled in with chemically synthesized oligonucleotides. Fragments of the coding sequence from more than one gene may be ligated together and expressed.

Signal sequences that dictate secretion of soluble proteins are particularly desirable as component parts of a recombinant sequence. For example, a chimeric protein may be expressed that includes one or more additional purification-facilitating domains. Such domains include, but are not limited to, metal-chelating domains that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex, Seattle WA). The inclusion of a cleavable-linker sequence such as ENTEROKINASEMAX (Invitrogen, San Diego CA) between the protein and the purification domain may also be used to recover the protein.

Suitable host cells may include, but are not limited to, mammalian cells such as Chinese Hamster

PA-0046 US

Ovary (CHO) and human 293 cells, insect cells such as Sf9 cells, plant cells such as Nicotiana tabacum, yeast cells such as Saccharomyces cerevisiae, and bacteria such as E. coli. For each of these cell systems, a useful vector may also include an origin of replication and one or two selectable markers to allow selection in bacteria as well as in a transformed eukaryotic host. Vectors for use in eukaryotic host cells may require the addition of 3' poly(A) tail if the cDNA lacks poly(A).

Additionally, the vector may contain promoters or enhancers that increase gene expression. Many promoters are known and used in the art. Most promoters are host specific and exemplary promoters includes SV40 promoters for CHO cells; T7 promoters for bacterial hosts; viral promoters and enhancers for plant cells; and PGH promoters for yeast. Adenoviral vectors with the rous sarcoma virus enhancer or retroviral vectors with long terminal repeat promoters may be used to drive protein expression in mammalian cell lines. Once homogeneous cultures of recombinant cells are obtained, large quantities of secreted soluble protein may be recovered from the conditioned medium and analyzed using chromatographic methods well known in the art. An alternative method for the production of large amounts of secreted protein involves the transformation of mammalian embryos and the recovery of the recombinant protein from milk produced by transgenic cows, goats, sheep, and the like.

In addition to recombinant production, proteins or portions thereof may be produced manually, using solid-phase techniques (Stewart *et al.* (1969) Solid-Phase Peptide Synthesis, WH Freeman, San Francisco CA; Merrifield (1963) J Am Chem Soc 5:2149-2154), or using machines such as the 431A peptide synthesizer (Applied Biosystems (ABI), Foster City CA). Proteins produced by any of the above methods may be used as pharmaceutical compositions to treat disorders associated with null or inadequate expression of the genomic sequence.

Screening and Purification Assays

A protein or a portion thereof encoded by the cDNA may be used to screen a library or a plurality of molecules or compounds for a ligand with specific binding affinity or to purify a molecule or compound from a sample. The protein or portion thereof employed in such screening may be free in solution, affixed to an abiotic or biotic substrate, or located intracellularly. For example, viable or fixed prokaryotic host cells that are stably transformed with recombinant nucleic acids that have expressed and positioned a protein on their cell surface can be used in screening assays. The cells are screened against a library or a plurality of ligands and the specificity of binding or formation of complexes between the expressed protein and the ligand may be measured. The ligands may be agonists, antagonists, antibodies, DNA molecules, enhancers, small drug molecules, immunoglobulins, inhibitors, mimetics, peptide nucleic acid molecules, peptides, pharmaceutical agents, proteins, and regulatory proteins, repressors, RNA molecules, ribozymes, transcription factors, or any

PA-0046 US

other test molecule or compound that specifically binds the protein. An exemplary assay involves combining the mammalian protein or a portion thereof with the molecules or compounds under conditions that allow specific binding and detecting the bound protein to identify at least one ligand that specifically binds the protein.

5 This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding the protein specifically compete with a test compound capable of binding to the protein or oligopeptide or fragment thereof. One method for high throughput screening using very small assay volumes and very small amounts of test compound is described in USPN 5,876,946. Molecules or compounds identified by screening may be used in a model system to evaluate their toxicity, diagnostic, or therapeutic potential.

10 The protein may be used to purify a ligand from a sample. A method for using a protein to purify a ligand would involve combining the protein or a portion thereof with a sample under conditions to allow specific binding, recovering the bound protein, and using an appropriate chaotropic agent to separate the protein from the purified ligand.

15 **Production of Antibodies**

A protein encoded by a cDNA of the invention may be used to produce specific antibodies. Antibodies may be produced using an oligopeptide or a portion of the protein with inherent immunological activity. Methods for producing antibodies include: 1) injecting an animal, usually goats, rabbits, or mice, with the protein, or an antigenically-effective portion or an oligopeptide thereof, to induce an immune response; 2) engineering hybridomas to produce monoclonal antibodies; 3) inducing in vivo production in the lymphocyte population; or 4) screening libraries of recombinant immunoglobulins. Recombinant immunoglobulins may be produced as taught in USPN 4,816,567.

20 Antibodies produced using the proteins of the invention are useful for the diagnosis of prepathologic disorders as well as the diagnosis of chronic or acute diseases characterized by abnormalities in the expression, amount, or distribution of the protein. A variety of protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies specific for proteins are well known in the art. Immunoassays typically involve the formation of complexes between a protein and its specific binding molecule or compound and the measurement of complex formation. Immunoassays may employ a two-site, monoclonal-based assay that utilizes monoclonal antibodies reactive to two noninterfering epitopes on a specific protein or a competitive binding assay (Pound (1998) Immunochemical Protocols, Humana Press, Totowa NJ).

30 Immunoassay procedures may be used to quantify expression of the protein in cell cultures, in

PA-0046 US

subjects with a particular disorder or in model animal systems under various conditions. Increased or decreased production of proteins as monitored by immunoassay may contribute to knowledge of the cellular activities associated with developmental pathways, engineered conditions or diseases, or treatment efficacy. The quantity of a given protein in a given tissue may be determined by performing immunoassays on freeze-thawed detergent extracts of biological samples and comparing the slope of the binding curves to binding curves generated by purified protein.

Antibody Arrays

In an alternative to yeast two hybrid system analysis of proteins, an antibody array can be used to study protein-protein interactions and phosphorylation. A variety of protein ligands are immobilized on a membrane using methods well known in the art. The array is incubated in the presence of cell lysate until protein:antibody complexes are formed. Proteins of interest are identified by exposing the membrane to an antibody specific to the protein of interest. In the alternative, a protein of interest is labeled with digoxigenin (DIG) and exposed to the membrane; then the membrane is exposed to anti-DIG antibody which reveals where the protein of interest forms a complex. The identity of the proteins with which the protein of interest interacts is determined by the position of the protein of interest on the membrane.

Antibody arrays can also be used for high-throughput screening of recombinant antibodies. Bacteria containing antibody genes are robotically-picked and gridded at high density (up to 18,342 different double-spotted clones) on a filter. Up to 15 antigens at a time are used to screen for clones to identify those that express binding antibody fragments. These antibody arrays can also be used to identify proteins which are differentially expressed in samples (de Wildt *et al.* (2000) Nat Biotechnol 18:989-94).

Assays Using Antibodies

Antibodies directed against antigenic determinant on a protein encoded by a cDNA of the invention may be used in assays to quantify the amount of protein found in a particular human cell. Such assays include methods utilizing the antibody and a label to detect expression level under normal or disease conditions. The antibodies may be used with or without modification, and labeled by joining them, either covalently or noncovalently, with a labeling moiety.

Protocols for detecting and measuring protein expression using either polyclonal or monoclonal antibodies are well known in the art. Examples include ELISA, RIA, fluorescent activated cell sorting (FACS) and arrays. Such immunoassays typically involve the formation of complexes between the protein and its specific antibody and the measurement of such complexes.

Labeling of Molecules for Assay

A wide variety of reporter molecules and conjugation techniques are known by those skilled in the art

PA-0046 US

and may be used in various cDNA, polynucleotide, protein, peptide or antibody assays. Synthesis of labeled molecules may be achieved using commercial kits for incorporation of a labeled nucleotide such as ³²P-dCTP, Cy3-dCTP or Cy5-dCTP or amino acid such as ³⁵S-methionine. Polynucleotides, cDNAs, proteins, or antibodies may be directly labeled with a reporter molecule by chemical conjugation to amines, thiols and other groups present in the molecules using reagents such as BIODIPY or FITC (Molecular Probes, Eugene OR).

The proteins and antibodies may be labeled for purposes of assay by joining them, either covalently or noncovalently, with a reporter molecule that provides for a detectable signal. A wide variety of labels and conjugation techniques are known and have been reported in the scientific and patent literature including, but not limited to USPN 3,817,837; USPN 3,850,752; USPN 3,939,350; USPN 3,996,345; USPN 4,277,437;

10 USPN 4,275,149; and USPN 4,366,241.

DIAGNOSTICS

The cDNAs, or fragments thereof, may be used to detect and quantify differential gene expression; absence, presence, or excess expression of mRNAs; or to monitor mRNA levels during therapeutic intervention. Disorders associated with altered expression include cancers, particularly neuroblastoma.

15 Expression Profiles

A gene expression profile comprises the expression of a plurality of cDNAs or proteins as measured using assay well known in the art. The cDNAs of the invention may be used as elements on a substrate to produce an expression profile. In one embodiment, the profile is used to diagnose or monitor the progression of disease. The differences between gene expression in healthy and diseased tissues or cells can be assessed 20 and cataloged.

For example, the cDNA or protein, may be labeled by standard methods and added to a biological sample from a patient under conditions for complex formation (specific binding). After an incubation period, the sample is washed and the amount of label (or signal) associated with complex formation, is quantified and compared with a standard value. If complex formation in the patient sample is significantly altered (higher or 25 lower) in comparison to either a normal or disease standard, then differential expression indicates the presence of a disorder.

In order to provide standards for establishing differential expression, normal and disease expression profiles are established. This is accomplished by combining a sample taken from normal subjects, either animal or human, with a cDNA or protein under conditions for complex formation to occur. Standards may 30 be obtained by comparing the expression levels from normal subject tissues with those from an experiment in which a known amount of a purified sequence is used. Standard expression levels obtained in this manner may be compared with those obtained from samples from patients who were diagnosed with a particular condition, disease, or disorder. Deviation from the standard toward those associated with a particular disorder

PA-0046 US

is used to diagnose that disorder.

By analyzing changes in patterns of gene expression, disease can be diagnosed at earlier stages before the patient is symptomatic. The invention can be used to formulate a prognosis and to design a treatment regimen. The invention can also be used to monitor the efficacy of treatment. For treatments with known side effects, the array is employed to improve the treatment regimen. A dosage is established that causes a change in genetic expression patterns indicative of successful treatment. Expression patterns associated with the onset of undesirable side effects are avoided. This approach may be more sensitive and rapid than waiting for the patient to show inadequate improvement, or to manifest side effects, before altering the course of treatment.

10 In another embodiment, animal models which mimic a human disease can be used to characterize expression profiles associated with a particular condition, disease, or disorder; or treatment of the condition, disease, or disorder. Novel treatment regimens may be tested in these animal models using arrays to establish and then follow expression profiles over time. In addition, arrays may be used with cell cultures or tissues removed from animal models to rapidly screen large numbers of candidate drug molecules, looking for ones 15 that produce an expression profile similar to those of known therapeutic drugs, with the expectation that molecules with the same expression profile will likely have similar therapeutic effects. Thus, the invention provides the means to rapidly determine the molecular mode of action of a drug.

Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies and in clinical trial or to monitor the treatment of an individual patient. Once the presence of 20 a condition is established and a treatment protocol is initiated, diagnostic assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in a normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

Gene Expression Profiles

25 A gene expression profile comprises a plurality of cDNAs and a plurality of detectable hybridization complexes, wherein each complex is formed by hybridization of one or more probes to one or more complementary nucleic acids in a sample. The cDNAs of the invention are used as elements on a array to analyze gene expression profiles. In one embodiment, the array is used to monitor the progression of disease. Researchers can assess and catalog the differences in gene expression between healthy and diseased tissues 30 or cells. By analyzing changes in patterns of gene expression, disease can be diagnosed at earlier stages before the patient is symptomatic. The invention can be used to formulate a prognosis and to design a treatment regimen. The invention can also be used to monitor the efficacy of treatment. For treatments with

PA-0046 US

known side effects, the array is employed to improve the treatment regimen. A dosage is established that causes a change in genetic expression patterns indicative of successful treatment. Expression patterns associated with the onset of undesirable side effects are avoided. This approach may be more sensitive and rapid than waiting for the patient to show inadequate improvement, or to manifest side effects, before altering the course of treatment.

Experimentally, expression profiles can also be evaluated by methods including, but not limited to, differential display by spatial immobilization or by gel electrophoresis, genome mismatch scanning, representational discriminant analysis, transcript imaging, and by protein or antibody arrays. Expression profiles produced by these methods may be used alone or in combination. The correspondence between mRNA and protein expression has been discussed by Zweiger (2001, Transducing the Genome. McGraw-Hill, San Francisco, CA) and Glavas et al. (2001; T cell activation upregulates cyclic nucleotide phosphodiesterases 8A1 and 7A3, Proc Natl Acad Sci 98:6319-6342) among others.

In another embodiment, animal models which mimic a human disease can be used to characterize expression profiles associated with a particular condition, disorder or disease; or treatment of the condition, disorder or disease. Novel treatment regimens may be tested in these animal models using arrays to establish and then follow expression profiles over time. In addition, arrays may be used with cell cultures or tissues removed from animal models to rapidly screen large numbers of candidate drug molecules, looking for ones that produce an expression profile similar to those of known therapeutic drugs, with the expectation that molecules with the same expression profile will likely have similar therapeutic effects. Thus, the invention provides the means to rapidly determine the molecular mode of action of a drug.

THERAPEUTICS

The cDNAs and fragments thereof can be used in gene therapy. cDNAs can be delivered ex vivo to target cells, such as cells of bone marrow. Once stable integration and transcription and or translation are confirmed, the bone marrow may be reintroduced into the subject. Expression of the protein encoded by the cDNA may correct a disorder associated with mutation of a normal sequence, reduction or loss of an endogenous target protein, or overexpression of an endogenous or mutant protein. Alternatively, cDNAs may be delivered in vivo using vectors such as retrovirus, adenovirus, adeno-associated virus, herpes simplex virus, and bacterial plasmids. Non-viral methods of gene delivery include cationic liposomes, polylysine conjugates, artificial viral envelopes, and direct injection of DNA (Anderson (1998) Nature 392:25-30; Dachs et al. (1997) Oncol Res 9:313-325; Chu et al. (1998) J Mol Med 76(3-4):184-192; Weiss et al. (1999) Cell Mol Life Sci 55(3):334-358; Agrawal (1996) Antisense Therapeutics, Humana Press, Totowa NJ; and August et al. (1997) Gene Therapy (Advances in Pharmacology, Vol. 40), Academic Press, San Diego CA).

In addition, expression of a particular protein can be regulated through the specific binding of a

PA-0046 US

fragment of a cDNA to a genomic sequence or an mRNA which encodes the protein or directs its transcription or translation. The cDNA can be modified or derivatized to any RNA-like or DNA-like material including peptide nucleic acids, branched nucleic acids, and the like. These sequences can be produced biologically by transforming an appropriate host cell with a vector containing the sequence of interest.

5 Molecules which regulate the activity of the cDNA or encoded protein are useful as therapeutics for neuroblastoma. Such molecules include agonists which increase the expression or activity of the polynucleotide or encoded protein, respectively; or antagonists which decrease expression or activity of the polynucleotide or encoded protein, respectively. In one aspect, an antibody which specifically binds the protein may be used directly as an antagonist or indirectly as a delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express the protein.

10 Additionally, any of the proteins, or their ligands, or complementary nucleic acid sequences may be administered as pharmaceutical compositions or in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act 15 synergistically to affect the treatment or prevention of the conditions and disorders associated with an immune response. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects. Further, the therapeutic agents may be combined with pharmaceutically-acceptable carriers including excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques 20 for formulation and administration used by doctors and pharmacists may be found in the latest edition of Remington's Pharmaceutical Sciences (Mack Publishing, Easton PA).

Model Systems

25 Animal models may be used as bioassays where they exhibit a phenotypic response similar to that of humans and where exposure conditions are relevant to human exposures. Mammals are the most common models, and most infectious agent, cancer, drug, and toxicity studies are performed on rodents such as rats or mice because of low cost, availability, lifespan, reproductive potential, and abundant reference literature. Inbred and outbred rodent strains provide a convenient model for investigation of the physiological consequences of underexpression or overexpression of genes of interest and for the development of methods 30 for diagnosis and treatment of diseases. A mammal inbred to overexpress a particular gene (for example, secreted in milk) may also serve as a convenient source of the protein expressed by that gene.

Transgenic Animal Models

Transgenic rodents that overexpress or underexpress a gene of interest may be inbred and used to

PA-0046 US

model human diseases or to test therapeutic or toxic agents. (See, e.g., USPN 5,175,383 and USPN 5,767,337.) In some cases, the introduced gene may be activated at a specific time in a specific tissue type during fetal or postnatal development. Expression of the transgene is monitored by analysis of phenotype, of tissue-specific mRNA expression, or of serum and tissue protein levels in transgenic animals before, during, 5 and after challenge with experimental drug therapies.

Embryonic Stem Cells

Embryonic (ES) stem cells isolated from rodent embryos retain the potential to form embryonic tissues. When ES cells such as the mouse 129/SvJ cell line are placed in a blastocyst from the C57BL/6 mouse strain, they resume normal development and contribute to tissues of the live-born animal. ES cells are 10 preferred for use in the creation of experimental knockout and knockin animals. The method for this process is well known in the art and the steps are: the cDNA is introduced into a vector, the vector is transformed into ES cells, transformed cells are identified and microinjected into mouse cell blastocysts, blastocysts are surgically transferred to pseudopregnant dams. The resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains.

Knockout Analysis

In gene knockout analysis, a region of a gene is enzymatically modified to include a non-natural intervening sequence such as the neomycin phosphotransferase gene (neo; Capecchi (1989) Science 244:1288-1292). The modified gene is transformed into cultured ES cells and integrates into the endogenous genome by homologous recombination. The inserted sequence disrupts transcription and translation of the 20 endogenous gene.

Knockin Analysis

ES cells can be used to create knockin humanized animals or transgenic animal models of human diseases. With knockin technology, a region of a human gene is injected into animal ES cells, and the human sequence integrates into the animal cell genome. Transgenic progeny or inbred lines are studied and treated 25 with potential pharmaceutical agents to obtain information on the progression and treatment of the analogous human condition.

As described herein, the uses of the cDNAs, provided in the Sequence Listing of this application, and their encoded proteins are exemplary of known techniques and are not intended to reflect any limitation on their use in any technique that would be known to the person of average skill in the art. Furthermore, the 30 cDNAs provided in this application may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known to the person of ordinary skill in the art, e.g., the triplet genetic code, specific base pair interactions, and the

PA-0046 US

like. Likewise, reference to a method may include combining more than one method for obtaining or assembling full length cDNA sequences that will be known to those skilled in the art. It is also to be understood that this invention is not limited to the particular methodology, protocols, and reagents described, as these may vary. It is also understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims. The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.

EXAMPLES**I Construction of cDNA Libraries**

RNA was purchased from Clontech Laboratories (Palo Alto CA) or isolated from various tissues. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL reagent (Invitrogen). The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated with either isopropanol or ethanol and sodium acetate, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In most cases, RNA was treated with DNase. For most libraries, poly(A) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (Qiagen, Valencia CA), or an OLIGOTEX mRNA purification kit (Qiagen). Alternatively, poly(A) RNA was isolated directly from tissue lysates using other kits, including the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene (La Jolla CA) was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Invitrogen) using the recommended procedures or similar methods known in the art. (See Ausubel, *supra*, Units 5.1 through 6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (APB) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of the pBLUESCRIPT phagemid (Stratagene), pSPORT1 plasmid (Invitrogen), or pINCY plasmid (Incyte Genomics). Recombinant plasmids were transformed into XL1-BLUE, XL1-BLUEMRF, or SOLR competent E. coli cells (Stratagene) or DH5 α , DH10B, or ELECTROMAX DH10B competent E. coli cells (Invitrogen).

In some cases, libraries were superinfected with a 5x excess of the helper phage, M13K07, according to the method of Vieira *et al.* (1987, Methods Enzymol 153:3-11) and normalized or subtracted using a

PA-0046 US

methodology adapted from Soares (1994, Proc Natl Acad Sci 91:9228-9232), Swaroop et al. (1991, Nucleic Acids Res 19:1954), and Bonaldo et al. (1996, Genome Research 6:791-806). The modified Soares normalization procedure was utilized to reduce the repetitive cloning of highly expressed high abundance cDNAs while maintaining the overall sequence complexity of the library. Modification included significantly 5 longer hybridization times which allowed for increased gene discovery rates by biasing the normalized libraries toward those infrequently expressed low-abundance cDNAs which are poorly represented in a standard transcript image (Soares, supra).

II Isolation and Sequencing of cDNA Clones

Plasmids were recovered from host cells by in vivo excision using the UNIZAP vector system 10 (Stratagene) or by cell lysis. Plasmids were purified using one of the following: the Magic or WIZARD MINIPREPS DNA purification system (Promega); the AGTC MINIPREP purification kit (Edge BioSystems, Gaithersburg MD); the QIAWELL 8, QIAWELL 8 Plus, or QIAWELL 8 Ultra plasmid purification systems, or the REAL PREP 96 plasmid purification kit (Qiagen). Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

15 Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao (1994) Anal Biochem 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

20 cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the CATALYST 800 thermal cycler (ABI) or the DNA ENGINE thermal cycler (MJ Research, Watertown MA) in conjunction with the HYDRA microdispenser (Robbins Scientific, Sunnyvale CA) or the MICROLAB 2200 system (Hamilton, Reno NV). cDNA sequencing reactions were prepared using reagents provided by APB or supplied in sequencing kits such as the PRISM BIGDYE cycle 25 sequencing kit (ABI). Electrophoretic separation of cDNA sequencing reactions and detection of labeled cDNAs were carried out using the MEGABACE 1000 DNA sequencing system (APB); the PRISM 373 or 377 sequencing systems (ABI) in conjunction with standard protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, supra, Unit 7.7).

30 III Extension of cDNA Sequences

Nucleic acid sequences were extended using the cDNA clones and oligonucleotide primers. One primer was synthesized to initiate 5' extension of the known fragment, and the other, to initiate 3' extension of

PA-0046 US

the known fragment. The initial primers were designed using OLIGO primer analysis software (Molecular Biology Insights, Cascade CO), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer

5 dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed. Preferred libraries are ones that have been size-selected to include larger cDNAs. Also, random primed libraries are preferred because they will contain more sequences with the 5' and upstream regions of genes. A randomly primed library is

10 particularly useful if an oligo d(T) library does not yield a full-length cDNA.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the DNA ENGINE thermal cycler (MJ Research). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg²⁺, (NH₄)₂SO₄, and β-mercaptoethanol, Taq DNA polymerase (APB), ELONGASE enzyme (Invitrogen), and Pfu DNA

15 polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B (Incyte Genomics): Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ (Stratagene) were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

20 The concentration of DNA in each well was determined by dispensing 100 μl PICOGREEN reagent (0.25% reagent in 1x TE, v/v; Molecular Probes) and 0.5 μl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA) and allowing the DNA to bind to the reagent. The plate was scanned in a FLUOROSKAN II (Labsystems Oy) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μl to 10 μl aliquot of the reaction mixture was analyzed by

25 electrophoresis on a 1% agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleic acids were desalting and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC18 vector (APB). For shotgun sequencing, the digested nucleic acids were

30 separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with AGARACE enzyme (Promega). Extended clones were religated using T4 DNA ligase (New England Biolabs, Beverly MA) into pUC18 vector (APB), treated with Pfu DNA polymerase (Stratagene) to fill-in

PA-0046 US

restriction site overhangs, and transformed into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carbenicillin liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (APB) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified using PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions described above. Samples were diluted with 20% dimethylsulfoxide (DMSO; 1:2, v/v), and sequenced using DYENAMIC energy 10 transfer sequencing primers and the DYENAMIC DIRECT cycle sequencing kit (APB) or the PRISM BIGDYE terminator cycle sequencing kit (ABI).

IV Assembly and Analysis of Sequences

Component nucleotide sequences from chromatograms were subjected to PHRED analysis (Phil Green, University of Washington, Seattle WA) and assigned a quality score. The sequences having at least a required quality score were subject to various pre-processing algorithms to eliminate low quality 3' ends, vector and linker sequences, polyA tails, Alu repeats, mitochondrial and ribosomal sequences, bacterial contamination sequences, and sequences smaller than 50 base pairs. Sequences were screened using the BLOCK 2 program (Incyte Genomics), a motif analysis program based on sequence information contained in the SWISS-PROT and PROSITE databases (Bairoch *et al.* (1997) Nucleic Acids Res 25:217-221; Attwood 20 *et al.* (1997) J Chem Inf Comput Sci 37:417-424).

Processed sequences were subjected to assembly procedures in which the sequences were assigned to bins, one sequence per bin. Sequences in each bin were assembled to produce consensus sequences, templates. Subsequent new sequences were added to existing bins using BLAST (Altschul, 1990 (*supra*); Altschul, 1993 (*supra*); Karlin *et al.* (1988) Proc Natl Acad Sci 85:841-845), BLASTn (vers.1.4, WashU), and 25 CROSMATCH software (Green, *supra*). Candidate pairs were identified as all BLAST hits having a quality score greater than or equal to 150. Alignments of at least 82% local identity were accepted into the bin. The component sequences from each bin were assembled using PHRAP (Green, *supra*). Bins with several overlapping component sequences were assembled using DEEP PHRAP (Green, *supra*).

Bins were compared against each other, and those having local similarity of at least 82% were 30 combined and reassembled. Reassembled bins having templates of insufficient overlap (less than 95% local identity) were re-split. Assembled templates were also subjected to analysis by STITCHER/EXON MAPPER algorithms which analyzed the probabilities of the presence of splice variants, alternatively spliced

PA-0046 US

exons, splice junctions, differential expression of alternative spliced genes across tissue types, disease states, and the like. These resulting bins were subjected to several rounds of the above assembly procedures to generate the template sequences found in the LIFESEQ GOLD database (Incyte Genomics).

The assembled templates were annotated using the following procedure. Template sequences were analyzed using BLASTn (vers. 2.0, NCBI) versus GBpri (GenBank vers. 116). "Hits" were defined as an exact match having from 95% local identity over 200 base pairs through 100% local identity over 100 base pairs, or a homolog match having an E-value equal to or greater than 1×10^{-8} . (The "E-value" quantifies the statistical probability that a match between two sequences occurred by chance). The hits were subjected to frameshift FASTx versus GENPEPT (GenBank version 109). In this analysis, a homolog match was defined as having an E-value of 1×10^{-8} . The assembly method used above was described in USSN 09/276,534, filed March 25, 1999, and the LIFESEQ GOLD user manual (Incyte Genomics).

Following assembly, template sequences were subjected to motif, BLAST, Hidden Markov Model (HMM; Pearson and Lipman (1988) Proc Natl Acad Sci 85:2444-2448; Smith and Waterman (*supra*), and functional analyses, and categorized in protein hierarchies using methods described in USSN 08/812,290, filed March 6, 1997; USSN 08/947,845, filed October 9, 1997; USPN 5,953,727; and USSN 09/034,807, filed March 4, 1998. Template sequences may be further queried against public databases such as the GenBank rodent, mammalian, vertebrate, eukaryote, prokaryote, and human EST databases.

V Selection of Sequences, Microarray Preparation and Use

Incyte clones represent template sequences derived from the LIFESEQ GOLD assembled human sequence database (Incyte Genomics). In cases where more than one clone was available for a particular template, the 5'-most clone in the template was used on the microarray. For the UNIGEM series microarrays (Incyte Genomics), Incyte clones were mapped to non-redundant Unigene clusters (Unigene database (build 46), NCBI; Shuler (1997) J Mol Med 75:694-698), and the 5' clone with the strongest BLAST alignment (at least 90% identity and 100 bp overlap) was chosen, verified, and used in the construction of the microarray. The UNIGEM V microarray (Incyte Genomics) contains 7075 array elements which represent 4610 annotated genes and 2,184 unannotated clusters. Table 1 shows the GenBank annotations for SEQ ID NOs:1-365 of this invention as produced by BLAST analysis.

To construct microarrays, cDNAs were amplified from bacterial cells using primers complementary to vector sequences flanking the cDNA insert. Thirty cycles of PCR increased the initial quantity of cDNAs from 1-2 ng to a final quantity greater than 5 μ g. Amplified cDNAs were then purified using SEPHACRYL-400 columns (APB). Purified cDNAs were immobilized on polymer-coated glass slides. Glass microscope slides (Corning, Corning NY) were cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled

PA-0046 US

water washes between and after treatments. Glass slides were etched in 4% hydrofluoric acid (VWR Scientific Products, West Chester PA), washed thoroughly in distilled water, and coated with 0.05% aminopropyl silane (Sigma-Aldrich) in 95% ethanol. Coated slides were cured in a 110°C oven. cDNAs were applied to the coated glass substrate using a procedure described in USPN 5,807,522. One microliter of 5 the cDNA at an average concentration of 100 ng/ul was loaded into the open capillary printing element by a high-speed robotic apparatus which then deposited about 5 nl of cDNA per slide.

Microarrays were UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene), and then washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites were blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (Tropix, Bedford MA) 10 for 30 minutes at 60°C followed by washes in 0.2% SDS and distilled water as before.

VI Preparation of SamplesTissues and cell lines:

The neuroblastoma primary tumor cultures (P4 and P67) were established as described by Sarkar and Nuchtern (2000; Cancer Res 60:1908-1913) and cultured in MEM with 10% Fetal Calf Serum and antibiotics. 15 The MYCN inducible neuroblastoma cell line TET21 derived from the SH-EP line was obtained from Dr. Manfred Schwab. The TET21 cells were grown in 10% serum/RPMI with penicillin and streptomycin as described by Lutz, supra). Tetracycline was used at a concentration of 1 μ M.

cDNA Northerns:

Total RNA from induced and non-induced TET21 cells was isolated using the RNEASY kit (Qiagen) 20 and reverse-transcribed using SUPERSCRIPT-II reverse transcriptase (Invitrogen) with the CDS and SMART-II primer oligonucleotides in the SMART cDNA synthesis kit (Clontech). The resulting cDNA was amplified for 15 cycles. This method of Franz et al. (1999; Nucleic Acid Res 27:e3) was used to maximize detection sensitivity for MCM7 and other messages upon MYCN induction and to efficiently use tumor mRNA available in limiting quantity. The number of amplification cycles was optimized with electrophoretic 25 analysis of the cDNA on 1.4 % agarose to prevent over-cycling.

Equal amounts of MYCN-induced and non-induced cDNA was electrophoresed and electroblotted onto nylon membranes. Probes for MYCN and MCM7 were generated from PCR amplified fragments (MCYN: 5'-CCTGCCGCCGAGCTCG-3' and reverse 5'-CTCGCTGGACTGAGCCCA-3', MCM7: 5'-AGCAGAACATACAGCTACCTG-3' and reverse 5'-CCCTTGTCTCCTAGAAGAGAG-3') and either 30 random hexamer labeled with α -P³²-CTP or labeled with alkaline phosphatase using ALKPHOSDIRECT (APB). Probes were hybridized at 42°C in ULTRAHYB hybridization buffer (Ambion) or alkaline phosphatase hybridization buffer overnight and washed. Probe signals were detected using a

PA-0046 USPHOSPHOMAGER cassette (APB) . Expression levels were normalized against the signal from β -actin.**Probe Preparation**

Total RNA was extracted from exponentially growing cultures using an RNEASY kit (Qiagen) according to the instructions of the manufacturer. Poly(A) RNA was purified using the OLIGOTEX mRNA kit (Qiagen). Each poly(A) RNA sample was reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/ μ l oligo-d(T) primer (21mer), 1x first strand buffer, 0.03 units/ μ l RNase inhibitor, 500 uM dATP, 500 uM dGTP, 500 uM dTTP, 40 uM dCTP, and 40 uM either dCTP-Cy3 or dCTP-Cy5 (APB). The reverse transcription reaction was performed in a 25 ml volume containing 200 ng poly(A) RNA using the GEMBRIGHT kit (Incyte Genomics). Specific control poly(A) RNAs (YCFR06, YCFR45, YCFR67, 5 YCFR85, YCFR43, YCFR22, YCFR23, YCFR25, YCFR44, YCFR26) were synthesized by *in vitro* transcription from non-coding yeast genomic DNA (W. Lei, unpublished). As quantitative controls, control mRNAs (YCFR06, YCFR45, YCFR67, and YCFR85) at 0.002ng, 0.02ng, 0.2 ng, and 2ng were diluted into reverse transcription reaction at ratios of 1:100,000, 1:10,000, 1:1000, 1:100 (w/w) to sample mRNA, 10 respectively. To sample differential expression patterns, control mRNAs (YCFR43, YCFR22, YCFR23, YCFR25, YCFR44, YCFR26) were diluted into reverse transcription reaction at ratios of 1:3, 3:1, 1:10, 10:1, 15 1:25, 25:1 (w/w) to sample mRNA. Reactions were incubated at 37°C for 2 hr, treated with 2.5 ml of 0.5M sodium hydroxide, and incubated for 20 minutes at 85°C to stop the reaction and degrade the RNA.

cDNAs were purified using two successive CHROMA SPIN 30 gel filtration spin columns (Clontech). Cy3- and Cy5-labeled reaction samples were combined as described below and ethanol 20 precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The cDNAs were then dried to completion using a SpeedVAC system (Savant Instruments, Holbrook NY) and resuspended in 14 μ l 5X SSC, 0.2% SDS.

VII Hybridization and Detection

Hybridization reactions contained 9 μ l of sample mixture containing 0.2 μ g each of Cy3 and Cy5 25 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The mixture was heated to 65°C for 5 minutes and was aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The microarrays were transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber was kept at 100% humidity internally by the addition of 140 μ l of 5x SSC in a corner of the chamber. The chamber containing the microarrays was incubated for about 6.5 hours at 60°C. 30 The microarrays were washed for 10 min at 45°C in low stringency wash buffer (1x SSC, 0.1% SDS), three times for 10 minutes each at 45°C in high stringency wash buffer (0.1x SSC), and dried.

Reporter-labeled hybridization complexes were detected with a microscope equipped with an Innova

PA-0046 US

70 mixed gas 10 W laser (Coherent, Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light was focused on the microarray using a 20X microscope objective (Nikon, Melville NY). The slide containing the microarray was placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm microarray used in the present example was scanned with a resolution of 20 micrometers.

5

In two separate scans, the mixed gas multiline laser excited the two fluorophores sequentially.

10

Emitted light was split, based on wavelength, into two photomultiplier tube detectors (PMT R1477; Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the microarray and the photomultiplier tubes were used to filter the signals. The emission maxima of the fluorophores used were 565 nm for Cy3 and 650 nm for Cy5. Each microarray was typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus was capable of recording the spectra from both fluorophores simultaneously.

15

The sensitivity of the scans was calibrated using the signal intensity generated by a cDNA control species. Samples of the calibrating cDNA were separately labeled with the two fluorophores and identical amounts of each were added to the hybridization mixture. A specific location on the microarray contained a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000.

20

The output of the photomultiplier tube was digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Norwood, MA) installed in an IBM-compatible PC computer. The digitized data were displayed as an image where the signal intensity was mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data was also analyzed quantitatively. Where two different fluorophores were excited and measured simultaneously, the data were first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

25

A grid was superimposed over the fluorescence signal image such that the signal from each spot was centered in each element of the grid. The fluorescence signal within each element was then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis was the GEMTOOLS gene expression analysis program (Incyte Genomics). Significance was defined as signal to background ratio exceeding 2x and area hybridization exceeding 40%.

30

VIII Data Analysis and Results

Array elements that exhibited at least 4-fold change in expression at one or more time points, a signal intensity over 250 units, a signal-to-background ratio of at least 2.5, and an element spot size of at least 40%

PA-0046 US

were identified as differentially expressed using the GEMTOOLS program (Incyte Genomics). Positive differential expression values (downregulation) represent non-amplified tumor (P4) relative to MYCN amplified tumor (P67). Negative differential expression values (upregulation) represent MYCN amplified tumor (P67) relative to non-amplified tumor (P4). Table 1 identifies upregulated and downregulated cDNAs.

- 5 The cDNAs are identified by their SEQ ID NO and TEMPLATE ID, and by the description associated with at least a fragment of a polynucleotide found in GenBank. The descriptions were obtained using the sequences of the Sequence Listing and BLAST analysis.

IX Further Characterization of Differentially Expressed cDNAs and Proteins

Clones were blasted against the LIFESEQ Gold 5.1 database (Incyte Genomics) and an Incyte template and its sequence variants were chosen for each clone. The template and variant sequences were blasted against GenBank database to acquire annotation. The nucleotide sequences were translated into amino acid sequences which were blasted against the GenPept and other protein databases to acquire annotation and characterization, i.e., structural motifs. Different templates identified in Table 1 may share an identical GenBank annotation and single clones may be mapped to more than one template. These templates represent related homologs or splice variants. Templates with no match to a sequence in the GenBank database are identified in Table 1 as "Incyte Unique".

Percent sequence identity can be determined electronically for two or more nucleic acid or amino acid sequences using the MEGALIGN program, a component of LASERGENE software (DNASTAR). The percent identity between two amino acid sequences is calculated by dividing the length of sequence A, minus the number of gap residues in sequence A, minus the number of gap residues in sequence B, into the sum of the residue matches between sequence A and sequence B, times one hundred. Gaps of low or of no homology between the two amino acid sequences are not included in determining percentage identity.

Sequences with conserved protein motifs may be searched using the BLOCKS search program. This program analyses sequence information contained in the Swiss-Prot and PROSITE databases and is useful for determining the classification of uncharacterized proteins translated from genomic or cDNA sequences (Bairoch, *supra*; Attwood, *supra*). PROSITE database is a useful source for identifying functional or structural domains that are not detected using motifs due to extreme sequence divergence. Using weight matrices, these domains are calibrated against the SWISS-PROT database to obtain a measure of the chance distribution of the matches.

30 The PRINTS database can be searched using the BLIMPS search program to obtain protein family "fingerprints". The PRINTS database complements the PROSITE database by exploiting groups of conserved motifs within sequence alignments to build characteristic signatures of different protein families.

PA-0046 US

For both BLOCKS and PRINTS analyses, the cutoff scores for local similarity were: >1300=strong, 1000-1300=suggestive; for global similarity were: p<exp-3; and for strength (degree of correlation) were: >1300=strong, 1000-1300=weak. Pfam is a large collection of multiple sequence alignments and hidden Markov models covering many common protein domains. Version 5.5 of Pfam (Sept 2000) contains 5 alignments and models for 2478 protein families, based on the Swissprot 38 and SP-TrEMBL 11 protein sequence databases.

X Other Hybridization Technologies and Analyses

Other hybridization technologies utilize a variety of substrates such as nylon membranes, capillary tubes, etc. Arranging cDNAs on polymer coated slides is described in Example V; sample cDNA preparation 10 and hybridization and analysis using polymer coated slides is described in examples VI and VII, respectively.

The cDNAs are applied to a membrane substrate by one of the following methods. A mixture of cDNAs is fractionated by gel electrophoresis and transferred to a nylon membrane by capillary transfer. Alternatively, the cDNAs are individually ligated to a vector and inserted into bacterial host cells to form a library. The cDNAs are then arranged on a substrate by one of the following methods. In the first method, 15 bacterial cells containing individual clones are robotically picked and arranged on a nylon membrane. The membrane is placed on LB agar containing selective agent (carbenicillin, kanamycin, ampicillin, or chloramphenicol depending on the vector used) and incubated at 37°C for 16 hr. The membrane is removed from the agar and consecutively placed colony side up in 10% SDS, denaturing solution (1.5 M NaCl, 0.5 M NaOH), neutralizing solution (1.5 M NaCl, 1 M Tris, pH 8.0), and twice in 2xSSC for 10 min each. The 20 membrane is then UV irradiated in a STRATALINKER UV-crosslinker (Stratagene).

In the second method, cDNAs are amplified from bacterial vectors by thirty cycles of PCR using primers complementary to vector sequences flanking the insert. PCR amplification increases a starting concentration of 1-2 ng nucleic acid to a final quantity greater than 5 µg. Amplified nucleic acids from about 400 bp to about 5000 bp in length are purified using SEPHACRYL-400 beads (APB). Purified nucleic acids 25 are arranged on a nylon membrane manually or using a dot/slot blotting manifold and suction device and are immobilized by denaturation, neutralization, and UV irradiation as described above.

Hybridization probes derived from cDNAs of the Sequence Listing are employed for screening cDNAs, mRNAs, or genomic DNA in membrane-based hybridizations. Probes are prepared by diluting the cDNAs to a concentration of 40-50 ng in 45 µl TE buffer, denaturing by heating to 100°C for five min and 30 briefly centrifuging. The denatured cDNA is then added to a REDIPRIME tube (APB), gently mixed until blue color is evenly distributed, and briefly centrifuged. Five microliters of [³²P]dCTP is added to the tube, and the contents are incubated at 37°C for 10 min. The labeling reaction is stopped by adding 5 µl of 0.2M

PA-0046 US

EDTA, and probe is purified from unincorporated nucleotides using a PROBEQUANT G-50 microcolumn (APB). The purified probe is heated to 100°C for five min and then snap cooled for two min on ice.

Membranes are pre-hybridized in hybridization solution containing 1% Sarkosyl and 1x high phosphate buffer (0.5 M NaCl, 0.1 M Na₂HPO₄, 5 mM EDTA, pH 7) at 55°C for two hr. The probe, diluted in 15 ml fresh hybridization solution, is then added to the membrane. The membrane is hybridized with the probe at 55°C for 16 hr. Following hybridization, the membrane is washed for 15 min at 25°C in 1mM Tris (pH 8.0), 1% Sarkosyl, and four times for 15 min each at 25°C in 1mM Tris (pH 8.0). To detect hybridization complexes, XOMAT-AR film (Eastman Kodak, Rochester NY) is exposed to the membrane overnight at -70°C, developed, and examined.

10 XI Expression of the Encoded Protein

Expression and purification of a protein encoded by a cDNA of the invention is achieved using bacterial or virus-based expression systems. For expression in bacteria, cDNA is subcloned into a vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the trp-lac (tac) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into bacterial hosts, such as BL21(DE3). Antibiotic resistant bacteria express the protein upon induction with IPTG. Expression in eukaryotic cells is achieved by infecting Spodoptera frugiperda (Sf9) insect cells with recombinant baculovirus, Autographica californica nuclear polyhedrosis virus. The polyhedrin gene of baculovirus is replaced with the cDNA by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of transcription.

For ease of purification, the protein is synthesized as a fusion protein with glutathione-S-transferase (GST; APB) or a similar alternative such as FLAG. The fusion protein is purified on immobilized glutathione under conditions that maintain protein activity and antigenicity. After purification, the GST moiety is proteolytically cleaved from the protein with thrombin. A fusion protein with FLAG, an 8-amino acid peptide, is purified using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak, Rochester NY).

XII Production of Specific Antibodies

A denatured protein from a reverse phase HPLC separation is obtained in quantities up to 75 mg. This denatured protein is used to immunize mice or rabbits following standard protocols. About 100 µg is used to immunize a mouse, while up to 1 mg is used to immunize a rabbit. The denatured protein is radioiodinated and incubated with murine B-cell hybridomas to screen for monoclonal antibodies. About 20 mg of protein is

PA-0046 US

sufficient for labeling and screening several thousand clones.

In another approach, the amino acid sequence translated from a cDNA of the invention is analyzed using PROTEAN software (DNASTAR) to determine regions of high antigenicity, essentially antigenic determinants of the protein. The optimal sequences for immunization are usually at the C-terminus, the
5 N-terminus, and those intervening, hydrophilic regions of the protein that are likely to be exposed to the external environment when the protein is in its natural conformation. Typically, oligopeptides about 15 residues in length are synthesized using an 431 peptide synthesizer (ABI) using Fmoc-chemistry and then coupled to keyhole limpet hemocyanin (KLH; Sigma-Aldrich) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester. If necessary, a cysteine may be introduced at the N-terminus of the peptide to
10 permit coupling to KLH. Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated goat anti-rabbit IgG.

Hybridomas are prepared and screened using standard techniques. Hybridomas of interest are detected by screening with radioiodinated protein to identify those fusions producing a monoclonal antibody
15 specific for the protein. In a typical protocol, wells of 96 well plates (FAST, Becton-Dickinson, Palo Alto CA) are coated with affinity-purified, specific rabbit-anti-mouse (or suitable anti-species Ig) antibodies at 10 mg/ml. The coated wells are blocked with 1% BSA and washed and exposed to supernatants from hybridomas. After incubation, the wells are exposed to radiolabeled protein at 1 mg/ml. Clones producing antibodies bind a quantity of labeled protein that is detectable above background.

20 Such clones are expanded and subjected to 2 cycles of cloning at 1 cell/3 wells. Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from the ascitic fluid by affinity chromatography on protein A (APB). Monoclonal antibodies with affinities of at least 10^8 M⁻¹, preferably 10^9 to 10^{10} M⁻¹ or stronger, are made by procedures well known in the art.

XIII Purification of Protein Using Specific Antibodies

25 Naturally occurring or recombinant protein is purified by immunoaffinity chromatography using antibodies specific for the protein. An immunoaffinity column is constructed by covalently coupling the antibody to CNBr-activated SEPHAROSE resin (APB). Media containing the protein is passed over the immunoaffinity column, and the column is washed using high ionic strength buffers in the presence of detergent to allow preferential absorbance of the protein. After coupling, the protein is eluted from the
30 column using a buffer of pH 2-3 or a high concentration of urea or thiocyanate ion to disrupt antibody/protein binding, and the protein is collected.

XIV Screening Molecules for Specific Binding with the cDNA or Protein

PA-0046 US

The cDNA or fragments thereof and the protein or portions thereof are labeled with ^{32}P -dCTP, Cy3-dCTP, Cy5-dCTP (APB), or BIODIPY or FITC (Molecular Probes), respectively. Candidate molecules or compounds previously arranged on a substrate are incubated in the presence of labeled nucleic or amino acid. After incubation under conditions for either a cDNA or a protein, the substrate is washed, and any position on the substrate retaining label, which indicates specific binding or complex formation, is assayed.

5 The binding molecule is identified by its arrayed position on the substrate. Data obtained using different concentrations of the nucleic acid or protein are used to calculate affinity between the labeled nucleic acid or protein and the bound molecule. High throughput screening using very small assay volumes and very small amounts of test compound is fully described in USPN 5,876,946.

10 All patents and publications mentioned in the specification are incorporated herein by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the 15 described modes for carrying out the invention that are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

TABLE 1

SEQ ID NO	Template ID	Clone ID	GenBank Hit	E-value	Annotation	Bal DE
1	1497123CB1	1497123	g1294782	1.00E-107	phosphomevalonate kinase [Homo sapiens]	89.3
2	2985802CB1	3553729	g3420846	0	fibronectin [Danio rerio]	70.2
3	475532.4	2859033	g439858	3.00E-35	Human MHC Class I HLA heavy chain [HLA-B-7301] mRNA, complete cds.	58.2
4	3138290CB1	1870965	g2388555	0	alpha2(I) collagen [Homo sapiens]	51.1
5	474310.40	1672744	g818	0	protein-glutamine gamma-glutamyltransferase [Bos taurus]	49.1
6	410580.16	1445767	g386997	0	prebeta-migrating plasminogen activator inhibitor [Homo sapiens]	41.4
7	337518.25	1674454	g180924	0	connective tissue growth factor [Homo sapiens]	40.5
8	1303783CB1	079576	g34388	1.00E-145	lipocortin (AA 1-346) [Homo sapiens]	36.5
9	1044033.4	1514989	g2181871	0	Gig1 protein [Homo sapiens]	35.5
10	1000222.31	690313	g861521	0	prostacyclin-stimulating factor (PSF) [Homo sapiens]	33.4
11	403873.4	2329216	g179967	1.00E-160	carbonic anhydrase VII [Homo sapiens]	33
12	1383105.12	4049957	g2340833	1.00E-114	SM22 alpha [Homo sapiens]	29.6
13	1383354.13	1572533	g69833729	1.00E-86	d1977B1.5 (myosin regulatory light chain 2, smooth muscle isoform) [Homo sapiens]	29.6
14	697785CB1	2495131	g307122	8.00E-77	lectin precursor [Homo sapiens]	28.8
15	420115CB1	1904751	g179646	0	complement component C1s [Homo sapiens]	28.8
16	1101453.2	2949427	g23398	3.00E-64	1-8U [Homo sapiens]	25.2
17	1399366.20	2055534	g5111869	0	thrombospondin [Mus musculus]	24.6
18	3072333CB1	1447903	g398164	1.00E-145	insulin-like growth factor binding protein 3 [Homo sapiens]	24.4
19	1270681.1	1804548	g2588789	1.00E-22	p27/WAF1 [Felis catus]	23.9
20	1505038CB1	1987358	g536898	1.00E-166	folistatin-related protein precursor [Homo sapiens]	23.2
21	1035602.5	1854220	g3004502	0	quiescin [Homo sapiens]	22.1
22	1330167.3	1001730	g32131	1.00E-121	putative p33 [Homo sapiens]	21.1
23	1003386CB1	1664320	g29539	0	precursor of Clr (AA -17 to 688) [Homo sapiens]	21.1
24	1097334.1	2483605	g1924982	0	integral membrane serine protease Seprase [Homo sapiens]	20.1
25	959142CB1	2804667	g2995138	0	thrombospondin 2 [Bos taurus]	20.1
26	1359783CB1	1798209	g458228	5.00E-75	extracellular protein [Homo sapiens]	19.9
27	0636466CB1	557012	g512778	0	protein with miniaxin activity [synthetic construct]	19.5
28	1519595CB1	2056395	g1518107	0	transforming growth factor induced protein [Oryctolagus cuniculus]	19.4
29	2054176CB1	3142736	g6070253	3.00E-41	Dickkopf-3 [Homo sapiens]	17.8
30	1312323CB1	1319608	g219898	6.00E-96	I-caldesmon II [Homo sapiens]	17.7
31	022404.25	1319608	g180194	9.00E-96	caldesmon [Homo sapiens]	17.7
32	1787335CB1	1958902	g5815461	0	insulin-like growth factor binding protein 5 protease [Rattus norvegicus]	17.5
33	1193648.7	1851696	g3273405	8.00E-79	laminin alpha 4 [Mus musculus]	17.1
34	1193648.1	1851696	g3168993	0	d1142L7.1 (Laminin Alpha 4 LIKE isoform 1) [Homo sapiens]	17.1
35	1867861CB1	1448051	g726324	0	fibrillin-1 [Mus musculus]	16.3

TABLE 1

SEQ ID NO	Template ID	Clone ID	GenBank Hit	E-value	Annotation	Bal DE
36	5511889CB1	1650238	g2612868	2.00E-94	down syndrome candidate region 1; one of four alternatively spliced exon 1 [Homo sapiens]	16.3
37	3094768CB1	2902903	g1177476	4.00E-67	interferon-inducible protein [Homo sapiens]	16.2
38	1256895CB1	1720056	g6996155	8.00E-81	prion protein (p27-30) [Homo sapiens]	15.5
39	2019981CB1	1733490	g188626	0	moesin B [Homo sapiens]	15.3
40	2708240CB1	3084122	g2654198	0	deleted in liver cancer-1 [Homo sapiens]	15.2
41	1092427.1	1313183	g339548	0	transforming growth factor-beta 1 binding protein precursor [Homo sapiens]	14.9
42	351841.7	1832047	g187189	0	lysyl oxidase [Homo sapiens]	14.7
43	022221.43	1314882	g4104232	0	collagen alpha3(VI) [Mus musculus]	14.5
44	2190217CB1	078783	g347576	1.00E-84	myosin regulatory light chain [Homo sapiens]	13.8
45	410910.3	2518178	g30097	1.00E-152	pro-alpha 1 (II) collagen (313 AA; AA 975-271c) [Homo sapiens]	13.7
46	1966280CB1	1700077	g339992	0	tumor necrosis factor [Homo sapiens]	13.6
47	430669.39	1572555	g207508	2.00E-95	alpha-tropomyosin 5b [Rattus norvegicus]	13.5
48	430669.23	1572555	g4884393	6.00E-83	hypothetical protein [Homo sapiens]	13.5
49	1870753CB1	782235	g1418928	1.00E-154	prepro-alpha(I) collagen [Homo sapiens]	13.1
50	3173735CB1	521139	g193440	0	guanylate binding protein isoform I [Mus musculus]	12.8
51	1330185.14	2868138	g182514	2.00E-90	ferritin light chain [Homo sapiens]	12.3
52	2314132CB1	3118643	g30082	1.00E-89	alpha 1(VIII) collagen [Homo sapiens]	12.1
53	2508205CB1	2057296	g5748581	0	d16SP5.1 (reticulocalbin 1, EF-hand calcium binding domain) [Homo sapiens]	12
54	3326672CB1	1995380	g1195483	1.00E-73	microsomal glutathione transferase [Homo sapiens]	11.9
55	234202.34	1995380	g306808	3.00E-78	glutathione S-transferase [Homo sapiens]	11.9
56	078242CB1	1319020	g693933	0	carbonate dehydratase [Homo sapiens]	11.8
57	220943.20	417451	g31441	0	Human mRNA for integrin beta 1 subunit.	11.8
58	1383320.13	1558081	g198466	0	type IV collagenase [Mus musculus]	11.5
59	3526170CB1	2242648	g181947	0	thyroid differentiation protein precursor [Homo sapiens]	11.5
60	184081.24	027775	g507252	6.00E-35	ferritin heavy chain [Homo sapiens]	11.2
61	1821331CB1	1394401	g895840	0	Irp [Homo sapiens]	10.9
62	3660006CB1	1720114	g31438	1.00E-153	integrin alpha 5 subunit precursor [Homo sapiens]	10.9
63	089172.13	3693273	g162694	0	aspartyl (asparaginyl) beta hydroxylase [Bos taurus]	10.8
64	3084563CB1	2852042	g181071	2.00E-89	cysteine-rich protein [Homo sapiens]	10.6
65	241227.17	1402715	g704441	1.00E-146	unknown [Homo sapiens]	10.4
66	348151.2	1618422	g38416	1.00E-143	cyclin D2 [Homo sapiens]	10.4
67	1720808CB1	2606307	g180825	1.00E-165	collagen type IV alpha 5 chain [Homo sapiens]	10.3
68	998552.6	459651	g2822169	1.00E-132	homeodomain protein HOXA9 [Homo sapiens]	10.3
69	040652.35	2508261	g8176525	1.00E-119	interferon-inducible myeloid differentiation transcriptional activator [Homo sapiens]	10.2
70	040652.36	2508261	g184569	0	interferon-gamma induced protein [Homo sapiens]	10.2

TABLE 1

SEQ ID NO	Template ID	Clone ID	GenBank Hit	E-value	Annotation	Bal DE
71	082/55CB1	522294	g8999300	0	gpStaf50 [Homo sapiens]	10.1
72	190144CB1	1668794	g487809	4.00E-78	cell surface protein [Homo sapiens]	9.9
73	234537.3	1718651	g3046875	0	ecto-5' -nucleotidase [Mus musculus]	9.6
74	1088425..1	162769	g188256	1.00E-134	cell surface glycoprotein [Homo sapiens] ¹	9.6
75	254547..1	3134070	g7634779	8.00E-58	HDCMA39P [Homo sapiens]	9.5
76	2676170CB1	3820761	g5552411	0	decorin variant A [Homo sapiens]	9.4
77	1092181..1	2105963	g307269	1.00E-120	HLA-DRB1 [Homo sapiens]	9.4
78	471362.33	1720149	g7239698	1.00E-138	myosin light chain kinase isoform 2 [Homo sapiens]	9.3
79	471362.27	1720149	g7239696	5.00E-86	myosin light chain kinase [Homo sapiens]	9.3
80	1162416..1	2102320	g211205	3.00E-37	asma gene product [Gallus gallus]	9.3
81	252151..12	1599344	g6706335	0	laminin gamma 1 precursor [Anopheles gambiae]	9.2
82	252151..7	1599344	g186964	4.00E-99	laminin B2 chain [Homo sapiens]	9.2
83	358892..1	2057260	g3550283	0	XRP2 protein [Homo sapiens]	9.2
84	1296867CB1	3506985	g180117	0	antigen CD36 [Homo sapiens]	9.1
85	337518..7	3506985	g180111	0	antigen CD36 [Homo sapiens]	9.1
86	1344279CB1	2771046	g544755	0	aminopeptidase N, APN {type II membrane protein} {EC 3.4.11.2} [Oryctolagus cuniculus]	9.1
87	2731776CB1	2057601	g7294319	0	CG6778 gene product [Drosophila melanogaster]	9.1
88	1090035..1	1994472	g673417	5.00E-66	class II antigen [Homo sapiens]	9
89	1089929..9	2683564	g5478222	1.00E-143	MHC class II antigen [Homo sapiens]	9
90	2723092CB1	2633207	g1805270	0	endothelial PAS domain protein 1 [Mus musculus]	8.9
91	2174489CB1	2173208	g180803	0	alpha-1 type IV collagen [Homo sapiens]	8.9
92	1253978CB1	1867652	g5441246	0	branching enzyme 1 [Phaseolus vulgaris]	8.8
93	2274011CB1	1909488	g7292213	5.00E-44	CG1275 gene product [Drosophila melanogaster]	8.8
94	3119737CB1	2733928	g36034	1.00E-110	rhoC coding region (AA 1-193) [Homo sapiens]	8.8
95	1384695..102	1514318	g37987	0	Human XIST, coding sequence 'a' mRNA (locus DXS399E).	8.7
96	257332CB1	1402228	g57381	0	T-plastin [Rattus norvegicus]	8.7
97	2972880CB1	1636171	g6475031	0	sushi-repeat-containing protein [Mus musculus]	8.5
98	550425CB1	550425	g1373427	0	FLT4 ligand DHM [Homo sapiens]	8.5
99	014284CB1	1822716	g4106126	0	dipeptidyl peptidase I [Canis familiaris]	8.5
100	1091854..7	1708528	g1203969	0	filamin [Homo sapiens]	8.4
101	138709..5	2844989	g6031212	0	heat shock protein hsp40 homolog [Homo sapiens]	8.4
102	375954..1	1404153	g1381792	0	H-cadherin [Homo sapiens]	8.4
103	126278CB1	3511216	g3201589	0	endoglin [Homo sapiens]	8.3
104	282761..16	3511216	g3201589	0	endoglin [Homo sapiens]	8.3
105	3090708CB1	1283532	g3805947	0	ST4 oncofetal trophoblast glycoprotein [Homo sapiens]	8.3

TABLE 1

SEQ ID NO	Template ID	Clone ID	GenBank Hit	E-value	Annotation	Bal DE
106	230062.4	1711206	g183084	6.00E-88	21 kd basic fibroblast growth factor (ctg start codon; put.); putative [Homo sapiens]	8.2
107	483043CB1	1854277	g1405893	0	MHC class I chain-related protein A [Homo sapiens]	8.1
108	348205.9	1854277	g1405893	1.00E-139	MHC class I chain-related protein A [Homo sapiens]	8.1
109	1256295.18	1702350	g403128	1.00E-91	[Human gadd45 gene, complete cds.], gene product [Homo sapiens]	8
110	875668CB1	1418741	g306805	0	G protein-coupled receptor kinase [Homo sapiens]	8
111	1180189.1	2664388	g4063630	0	Homo sapiens clone IMAGE 286356.	8
112	3109992CB1	2483173	g37637	1.00E-178	VAC protein (AA 1-320) [Homo sapiens]	8
113	1250434CB1	1711151	g6636317	0	hypoxia-inducible factor 1 alpha [Homo sapiens]	7.8
114	1327838.1	3721987	g2947054	1.00E-18	Gene product with similarity to Rat F8 [Homo sapiens]	7.7
115	2021477CB1	2190284	g1669547	2.00E-91	RBP-MS/type 1 [Homo sapiens]	7.7
116	235171.20	1940994	g1663704	0	KIAA0242 protein [Homo sapiens]	7.7
117	149832CB1	604856	g494989	1.00E-152	nicotinamide N-methyltransferase [Homo sapiens]	7.6
118	1759127CB1	1759127	g409059	0	Iysyl hydroxylase [Rattus norvegicus]	7.6
119	2048551CB1	2048551	g1495463	1.00E-68	H.sapiens mRNA for metallothionein isoform 1R.	7.6
120	3282941CB1	155904	g3599521	4.00E-77	musculin [Homo sapiens]	7.6
121	2733135CB1	2806166	g291888	0	cathepsin B [Homo sapiens]	7.5
122	2176269CB1	1405940	g5852295	0	Iysyl hydroxylase isoform 2 [Mus musculus]	7.5
123	1218607CB1	477045	g1030053	1.00E-149	rtpv-1 [Homo sapiens]	7.5
124	1553795CB1	1906574	g1022323	0	collagen alpha-2(IV) chain [Mus musculus]	7.4
125	238538.22	1906574	g8101724	9.00E-40	canstatin [Homo sapiens]	7.4
126	246546.9	2936505	g3043597	0	Homo sapiens mRNA for KIAA0537 protein, complete cds.	7.4
127	234223.14	1672442	g219510	0	collagen alpha 1(Y) chain precursor [Homo sapiens]	7.2
128	2054053CB1	2054053	g181123	1.00E-105	cleavage signal 1 protein [Homo sapiens]	7.1
129	1613766CB1	1640161	g65633252	2.00E-32	G-protein gamma-12 subunit [Homo sapiens]	7.1
130	233454.3	1636639	g4519621	1.00E-67	OASIS protein [Mus musculus]	7.1
131	347699.13	1358285	g551122	0	utio [Mus musculus]	7
132	3531583CB1	1358285	g238775	0	putative tyrosine kinase receptor=UFO [human, NIH3T3, Peptide, 894 aa] [Homo sapiens]	7
133	407096.14	630625	g2832346	0	thioredoxin reductase [Homo sapiens]	7
134	482411.26	2304121	g999454	0	TX protease precursor [Homo sapiens]	6.9
135	482411.25	2304121	g903934	0	cysteine protease [Homo sapiens]	6.9
136	1258943CB1	434771	g1377894	0	OB-cadherin-1 [Homo sapiens]	6.9
137	1327030.1	450574	g829623	3.00E-86	myosin regulatory light chain [Homo sapiens]	6.9
138	025595.22	1962971	g8170714	0	laminin beta 2 chain; S-laminin [Homo sapiens]	6.9
139	995174.1	1975129	g6580411	6.00E-39	dL467L1.2 (vesicle-associated membrane protein 3 (cellubrevin)) [Homo sapiens]	6.8
140	1709732CB1	269456	g29626	0	CALLA protein (AA 1 - 750) [Homo sapiens]	6.7

TABLE 1

SEQ ID NO	Template ID	Clone ID	GenBank Hit	E-value	Annotation	Bal DE
141	1040610.4	692827	g36386	1.00E-131	SB-2-beta precursor polypeptide (aa -29 to 229) [Homo sapiens]	6.7
142	055498.6	1865767	g2769562	0	ZYG homologue [Homo sapiens]	6.7
143	181172CB1	2503037	g484051	1.00E-121	placental protein 5 (PP5) [Homo sapiens]	6.6
144	2705515CB1	1846209	g184657	0	transfer RNA-Trp synthetase [Homo sapiens]	6.5
145	480228.3	1997250	g339899	0	Human transposon-like element mRNA.	6.5
146	360929.39	063038	g338336	1.00E-98	spermidine/spermine N1-acetyltransferase [Homo sapiens]	6.5
147	1989087CB1	1603057	g37265	0	TRAM protein [Homo sapiens]	6.5
148	995068.16	1904994	g546088	0	CAP, 38 kda intracellular serine proteinase inhibitor [Homo sapiens]	6.4
149	1217216.1	1976279	g1297330	1.00E-140	DOC-2 [Homo sapiens]	6.4
150	474426.5	1281473	g1946347	0	RNA polymerase II elongation factor ELL2 [Homo sapiens]	6.4
151	350521.22	2078364	g3721878	0	DR5 [Homo sapiens]	6.4
152	1075592.6	1686585	g505589	1.00E-154	insulin-like growth factor binding protein 5 (IGFBP5) gene product [Homo sapiens]	6.4
153	1485867CB1	1959565	g5499721	0	eRF1 [Homo sapiens]	6.4
154	2515360CB1	1887959	g2370202	0	procollagen alpha 2(V) [Homo sapiens]	6.3
155	3290944CB1	3598222	g6165882	0	collagen type XI alpha-1 isoform A [Homo sapiens]	6.3
156	441206.15	2849603	g6492130	0	urokinase receptor-associated protein uPARAP [Homo sapiens]	6.3
157	1712327CB1	1712327	g202404	0	Wnt-5a [Mus musculus]	6.2
158	1393778CB1	2056987	g212383	0	myosin heavy chain [Gallus gallus]	6.1
159	480127.44	2056987	g189036	7.00E-11	nonmuscle myosin heavy chain (NMHC) [Homo sapiens]	6.1
160	1870941CB1	1870941	g297408	0	P63 protein [Homo sapiens]	6.1
161	2495110CB1	3176845	g3869113	0	TRKA [Homo sapiens]	6.1
162	034711.3	3425195	g7020611	0	unnamed protein product [Homo sapiens]	6.1
163	251776.14	418731	g3478697	0	integrin beta-5 [Mus musculus]	6.1
164	239511.5	1821971	g189730	0	platelet-derived growth factor receptor [Homo sapiens]	6.1
165	989878.1	1997703	g6563408	0	connexin 43 [Homo sapiens]	6
166	1558664CB1	2018222	g34656	1.00E-113	MHC-encoded proteasome subunit gene [Homo sapiens]	6
167	3602501CB1	3602501	g200882	0	retinoid X receptor-gamma [Mus musculus]	6
168	5549580CB1	1736926	g29424	0	beta-1,4-galactosyltransferase (AA -77 to 323) [Homo sapiens]	6
169	2687977CB1	1526282	g6666043	1.00E-55	NMB [Homo sapiens]	6
170	3168062CB1	1662688	g1388197	1.00E-117	low-Mr GTP-binding protein Rab32 [Homo sapiens]	5.9
171	245367.2	3215205	g4039117	9.00E-64	PEA-15 protein [Cricetulus griseus]	5.9
172	470587CB1	3940755	g179948	0	cathepsin D [Homo sapiens]	5.9
173	1631074CB1	064286	g4239883	0	Glutamine:fructose-6-phosphate amidotransferase [Homo sapiens]	5.8
174	347829.12	185448	g517179	0	YAP65 (Yes-associated protein of 65 kDa MW) [Mus musculus]	5.7
175	347699.11	2058242	g238775	0	putative tyrosine kinase receptor=UFO [human, NIH3T3, Peptide, 894 aa] [Homo sapiens]	5.7

TABLE 1

SEQ ID NO	Template ID	Clone ID	GenBank Hit	E-value	Annotation	Bal DE
176	I251672..1	1453450	g37227	0	tenascin [Homo sapiens]	5.6
177	I291022CBI	1291022	g13336027	0	ICE-LAP6 [Homo sapiens]	5.5
178	237405.19	2380381	g602703	1.00E-175	2,4-dienoyl-CoA reductase [Homo sapiens]	5.5
179	2685676CBI	2513883	g517350	0	H.sapiens MTIX gene for metallothionein 1X.	5.5
180	0106722CBI	549196	g180130	0	cell adhesion molecule [Homo sapiens]	5.4
181	234630.58	549196	g7705157	0	CD44R4 [Homo sapiens]	5.4
182	332595.5	3249851	g2979420	0	PCDH7 (BH-Pcdh) b [Homo sapiens]	5.4
183	332595.8	3249851	g3513312	0	BH-protocadherin-a [Mus musculus]	5.4
184	335086..1	3602403	g1543068	0	CHASE [Homo sapiens]	5.4
185	1342493CBI	1453748	g6381989	0	adipocyte-derived leucine aminopeptidase [Homo sapiens]	5.4
186	232691.20	2505425	g190877	1.00E-102	ras-like protein [Homo sapiens]	5.4
187	238814.2	1417211	g1418782	0	erm [Homo sapiens]	5.3
188	201571..1	959745	g2072181	0	Rat osteoprotegerin (OPG) protein, complete sequence [Rattus norvegicus]	5.3
189	199882.5	1449824	g2668615	0	similar to drosophila peroxidasin precursor (PID:g53.1385) [Caenorhabditis elegans]	5.3
190	237487.22	2380042	g791047	2.00E-60	gamma subunit of sodium potassium ATPase like [Homo sapiens]	5.2
191	237487.21	2380042	g791047	3.00E-51	gamma subunit of sodium potassium ATPase like [Homo sapiens]	5.2
192	305557CBI	029564	g2665792	5.00E-91	caveolin-2 [Homo sapiens]	5.2
193	1378745CBI	147184	g162779	0	calpastatin I heavy chain (p36) [Bos taurus]	5.2
194	1818836CBI	1818836	g984287	0	NDP52 [Homo sapiens]	5.2
195	137946..3	690994	g7243027	1.00E-168	KIAA1323 protein [Homo sapiens]	5.2
196	2110909CBI	2825369	g165009	0	progesterone-induced protein [Oryctolagus cuniculus]	5.2
197	200578..1	1397926			Incyte Unique	5.2
198	259592CBI	197207	g5911857	1.00E-145	hypothetical protein [Homo sapiens]	5.2
199	5584521CBI	1965863	g219925	1.00E-76	MIG-24 precursor [Homo sapiens]	5.1
200	399428..7	1491445	g3777545	0	nonsyndromic hearing impairment protein [Mus musculus]	5.1
201	117509..4	3012290	g1054903	1.00E-156	gamma-sacroglycan [Homo sapiens]	5.1
202	3255458CBI	1597330	g2804273	0	alpha actinin 4 [Homo sapiens]	5.1
203	1430889CBI	1856520	g4107433	1.00E-120	hypothetical protein [Homo sapiens]	5
204	445048..6	1856520	g4218185	1.00E-124	hypothetical protein [Homo sapiens]	5
205	4946593CBI	2852818	g337767	0	cerebroside sulfate activator protein [Homo sapiens]	5
206	350605..45	4114209	g453180	0	lamin A [Rattus norvegicus]	5
207	1413644CBI	1413644	g975311	0	adenyl cyclase-associated protein 2 [Rattus norvegicus]	5
208	984009..2	1446475	g1225979	0	H.sapiens mRNA for HMGI-C protein.	4.9
209	627662CBI	1631511	g4102182	0	phosphoenolpyruvate carboxykinase [Mus musculus]	4.9
210	1382932..11	2175008	g1155011	0	nitrogen [Homo sapiens]	4.9

TABLE 1

SEQ ID NO	Template ID	Clone ID	GenBank Hit	E-value	Annotation	Bal DE
211	2721850CB1	1624024	g 1542883	1.00E-86	progression associated protein [Homo sapiens]	4.9
212	994902..1	2059691	g 2584789	4.00E-18	vacuolar proton-ATPase subunit M9.2 [Homo sapiens]	4.9
213	442744..17	1610993	g 183002	0	guanylate binding protein isoform I [Homo sapiens]	4.8
214	442744..21	1610993	g 193440	0	guanylate binding protein isoform I [Mus musculus]	4.8
215	1908920CB1	2134356	g 1694828	2.00E-40	S100 calcium-binding protein A13 (S100A13) [Homo sapiens]	4.8
216	399101..31	2134356	g 1694828	1.00E-40	S100 calcium-binding protein A13 (S100A13) [Homo sapiens]	4.8
217	183198CB1	924319	g 793841	1.00E-172	nuclear protein [Homo sapiens]	4.8
218	1397781..7	1522716	g 340219	0	vimentin [Homo sapiens]	4.8
219	899496..9	812141	g 183613	0	granulin [Homo sapiens]	4.8
220	2111330CB1	1975209	g 1617319	4.00E-81	vasodilator-stimulated phosphoprotein [Homo sapiens]	4.8
221	331591..1	2452650	g 2655039	6.00E-61	tumor suppressing STF cDNA 3 [Homo sapiens]	4.8
222	337119..8	2488567	g 179407	1.00E-134	brain-derived neurotrophic factor [Homo sapiens]	4.8
223	245011..11	2232471	g 4193946	1.00E-87	P35rj [Homo sapiens]	4.7
224	1988468CB1	2232471	g 4193946	2.00E-88	p35sj [Homo sapiens]	4.7
225	331470..8	1457726	g 3043708	0	KIAA0592 protein [Homo sapiens]	4.7
226	411388CB1	591358	g 182483	1.00E-112	prefibroblast collagenase inhibitor [Homo sapiens]	4.7
227	253450..9	1347232	g 4426629	0	protocadherin [Rattus norvegicus]	4.7
228	351209..16	3686211	g 179095	0	acid sphingomyelinase [Homo sapiens]	4.7
229	2124320CB1	2204916	g 6573256	0	coatomer protein gamma2-COP [Mus musculus]	4.7
230	903876..1	548019	g 8248854	0	JAK1 protein tyrosine kinase [Mus sp.]	4.7
231	1238339CB1	2108793	g 541613	1.00E-119	platelet-endothelial tetraspan antigen 3 [Homo sapiens]	4.6
232	245310..36	2108793	g 541613	1.00E-125	platelet-endothelial tetraspan antigen 3 [Homo sapiens]	4.6
233	2696735CB1	2696735	g 1783205	1.00E-160	calponin [Homo sapiens]	4.6
234	338036..2	1449054	g 808915	1.00E-156	tumor necrosis factor receptor type 1 associated protein [Homo sapiens]	4.6
235	236484..15	1922533	g 66336498	0	signal transducer and activator of transcription 1; STAT1 [Rattus norvegicus]	4.6
236	232719..2	537580	g 2582830	0	alpha 1 integrin [Gallus gallus]	4.6
237	462249..1	1830083	g 5410274	0	hypothetical 19.5 kDa protein [Homo sapiens]	4.6
238	1187408..1	030672	g 178084	1.00E-125	adenyl cyclase-associated protein [Homo sapiens]	4.6
239	627856CB1	1559756	g 2665519	0	tyrosyl-tRNA synthetase [Homo sapiens]	4.6
240	553078CB1	1985104	g 5823591	0	adipophilin [Bos taurus]	4.6
241	048612..15	1975268	g 206667	0	phosphoenolpyruvate carboxykinase [Rattus norvegicus]	4.5
242	048612..12	1975268	g 307333	1.00E-100	phosphoenolpyruvate carboxykinase [Homo sapiens]	4.5
243	1099779..1	1612306	g 2662375	0	oligosaccharyltransferase [Homo sapiens]	4.5
244	1520855CB1	179929	g 1477651	0	plectin [Homo sapiens]	4.5
245	1179282..1	2870970	Ircyte Unique			4.5

TABLE 1

SEQ ID NO	Template ID	Clone ID	GenBank Hit	E-value	Annotation	Bal DE
246	2770449CB1	1658320	g497174	0	beta-hexosaminidase [Mus musculus]	4.5
247	1430336CB1	030291	g178699	1.00E-180	annexin IV (placental anticoagulant protein II) [Homo sapiens]	4.5
248	903105.6	544213	g7021449	1.00E-126	steroid sensitive gene-1 protein [Rattus norvegicus]	4.5
249	1327417.14	2211625	g186513	3.00E-28	interferon-gamma [Homo sapiens]	4.4
250	1327417.10	2211625	g186513	1.00E-121	interferon-gamma [Homo sapiens]	4.4
251	230712.24	2814551	g2274966	0	Cdc42-interacting protein 4 [Homo sapiens]	4.4
252	982520.1	2986240	g7373532	4.00E-93	dJ136O14.2 (collagen, type X, alpha 1) [Homo sapiens]	4.4
253	311807CB1	821141	g7295855	0	CG17259 gene product [Drosophila melanogaster]	4.4
254	1479370CB1	1626460	g49944	0	mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase [Mus musculus]	4.4
255	2993696CB1	2884613	g6900104	0	glucose-regulated protein [Homo sapiens]	4.4
256	4004223CB1	1810945	g452320	1.00E-114	rab 13 [Homo sapiens]	4.4
257	453835.19	1723035	g6822272	8.00E-69	Ras negative regulator Rabex-5/Rin2 [Mus musculus]	4.4
258	391741.16	1634279	g36061	0	peptide transporter [Homo sapiens]	4.3
259	391741.64	1634279	g36061	0	peptide transporter [Homo sapiens]	4.3
	1382958.26	3876715	g300169	0	APP=amyloid precursor protein homolog [human, placenta, Peptide, 763 aa] [Homo sapiens]	4.3
260						
261	232567.4	1577614	g404024	0	folistatin [Bos taurus]	4.3
262	1720770CB1	2189762	g7688699	1.00E-116	RER1 protein [Homo sapiens]	4.3
263	253987.19	700559	g395338	2.00E-55	helix-loop-helix protein [Homo sapiens]	4.2
264	2047630CB1	1381654	g3341715	0	asparagine synthetase [Homo sapiens]	4.2
265	238203.11	999864	g340237	0	vinculin [Homo sapiens]	4.2
266	899410.5	1724967	g4165326	0	plasma membrane calcium ATPase isoform 1 [Homo sapiens]	4.2
267	474311.3	2736056	g1657752	0	FE65-like protein [Homo sapiens]	4.2
268	2169835CB1	1003486	g558999	0	Shp52 [Mus musculus]	4.1
269	290021.11	1003486	g1899055	1.00E-153	p66shc [Homo sapiens]	4.1
270	267324CB1	2132217	g1905874	0	carboxyl terminal LIM domain protein [Homo sapiens]	4.1
271	2119372CB1	1889060	g402666	0	calpain II 80 kDa subunit [Rattus norvegicus]	4.1
272	2818482CB1	2668334	g36061	0	peptide transporter [Homo sapiens]	4.1
273	1330231.11	2594308	g430756	1.00E-116	ME491 /CD63 antigen [Homo sapiens]	4.1
274	1330117.5	692201	g1791289	1.00E-137	MHC class II HLA-DQ [Homo sapiens]	4.1
275	233402.3	2056290	g1663726	0	MNB [Homo sapiens]	4.1
276	1622313CB1	1901061	g5880317	0	lysyl hydroxylase 3 [Mus musculus]	4.1
277	2939887CB1	1375115	g1235559	0	responsible for hereditary multiple exotosis [Mus musculus]	4.1
278	1804120CB1	1901095	g4959705	0	fibulin-2 [Mus musculus]	4
279	245485.12	1901095	g4884120	1.00E-129	hypothetical protein [Homo sapiens]	4

TABLE 1
PA-0046 US

SEQ ID	NO	Template ID	Clone ID	GenBank Hit	E-value	Annotation	Bal DE
280	1283395CB1	015834	g3064263	0	protein 4.1G [Mus musculus]	4	-4
281	036391.3	399035	g37074	1.00E-159	transcription elongation factor [Homo sapiens]	-4	-4
282	036391.13	399035	g37074	1.00E-171	transcription elongation factor [Homo sapiens]	-4	-4
283	474435.16	1610523	g307155	2.00E-86	MAC30 [Homo sapiens]	-4.1	-4.1
284	2495292CB1	2495292	g2267585	0	transcription intermediary factor 1 [Homo sapiens]	-4.2	-4.2
285	251651.4	1645766	g456090	2.00E-76	effector cell protease receptor 1 [Homo sapiens]	-4.2	-4.2
286	5408483CB1	3493061	g297529	0	NF-M [Mus musculus]	-4.2	-4.2
287	347876.6	103669	g1184107	0	DNA replication initiator protein [Xenopus laevis]	-4.3	-4.3
288	1289007CB1	1986737	g6690095	1.00E-145	tetraspanin protein [Homo sapiens]	-4.3	-4.3
289	233301.18	814216	g180173	0	putative [Homo sapiens]	-4.4	-4.4
290	2157771CB1	2825556	g199023	0	microtubule associated protein 2 [Mus musculus]	-4.4	-4.4
291	2958028CB1	1569804	g62966	0	NF-E1 [Gallus gallus]	-4.4	-4.4
292	233811.8	1569804	g639594	0	GATA-2 transcription factor {3' flanking region, exon 6} [Homo sapiens]	-4.4	-4.4
293	1270302CB1	1486358	g214862	0	beta-tubulin [Xenopus laevis]	-4.4	-4.4
294	067163CB1	1384823	g29979	4.00E-43	Cks1 protein homologue [Homo sapiens]	-4.4	-4.4
295	002387CB1	2781405	g387005	1.00E-139	proliferating cell nuclear antigen (PCNA) [Homo sapiens]	-4.4	-4.4
296	2798854CB1	4385292	g5262584	0	hypothetical protein [Homo sapiens]	-4.4	-4.4
297	1292280CB1	3496395	g4164381	0	nicotinic acetylcholine receptor alpha-3 subunit [Homo sapiens]	-4.5	-4.5
298	979248.2	3496395		Incyte Unique		-4.5	-4.5
299	236240.3	1850531	g4325180	1.00E-109	tetraspan NET-6 [Homo sapiens]	-4.5	-4.6
300	234427.4	1616315	g1507672	0	GS3955 [Homo sapiens]	-4.6	-4.6
301	234427.7	1616315	g1507672	9.00E-60	GS3955 [Homo sapiens]	-4.6	-4.6
302	411205.16	160410	g2865520	0	protein regulating cytokinesis 1; PRC1 mRNA, complete cds [Homo sapiens]	-4.6	-4.6
303	411205.5	160410	g2865521	0	protein regulating cytokinesis 1; PRC1 [Homo sapiens]	-4.6	-4.6
304	238854.23	1369473	g7707424	1.00E-117	synaxin 18 [Homo sapiens]	-4.6	-4.6
305	405008.1	726201	g5926703	4.00E-17	Homo sapiens genomic DNA, chromosome 6p21.3, HLA Class I region, section 15/20.	-4.6	-4.6
306	372981.9	1576329	g3901272	3.00E-56	ZW10 interactor Zwint [Homo sapiens]	-4.7	-4.7
307	345125.8	180439	g190426	0	protein phosphatase-2A subunit-beta [Homo sapiens]	-4.8	-4.8
308	345125.17	180439	g1777373	3.00E-45	B-regulatory subunit of protein phosphatase 2A [Rattus norvegicus]	-4.8	-4.8
309	1723834CB1	1723834	g434753	0	KIAA0030 [Homo sapiens]	-4.9	-4.9
310	407588.2	1640108	g1035015	1.00E-112	H.sapiens CpG island DNA genomic Msc1 fragment, clone 71a7, reverse read cpg71a7.rtl.a.	-5	-5
311	1970111CB1	1970111	g286013	0	KIAA0008 [Homo sapiens]	-5.1	-5.1
312	058208CB1	467621	g882223	0	tradin [Homo sapiens]	-5.2	-5.2
313	333461.2	4003342	g559715	0	KIAA0074 [Homo sapiens]	-5.2	-5.2
314	002940CB1	161207	g3402293	0	aurora and IP1-like midbody-associated protein kinase-1 [Homo sapiens]	-5.2	-5.2

TABLE 1

SEQ ID NO	Template ID	Clone ID	GenBank Hit	E-value	Annotation	Bal DE
315	365153CB1	2375329	g339560	1.00E-178	bone morphogenetic protein 5 [Homo sapiens]	-5.6
316	034181CB1	1316528	g190267	0	Poly(ADP-ribose) polymerase [Homo sapiens]	-5.7
317	264633.20	1709017	g4378022	2.00E-84	putative WHSC1 protein [Homo sapiens]	-5.8
318	264633.19	1709017	g6683808	0	MMSET type I [Homo sapiens]	-5.8
319	17605666CB1	2657680	g1907393	2.00E-79	proneurotensin/proneuromedin N [Homo sapiens]	-5.8
320	3296553CB1	173904	g609535	0	66 kDa neurofilament protein NF-66 [Mus musculus]	-5.8
321	199471.2	2414624	g1575534	1.00E-112	Mad2 [Homo sapiens]	-5.8
322	1558165CB1	1403041	g687590	2.00E-36	transmembrane protein [Homo sapiens]	-5.9
323	988665.6	2219234	g2827203	1.00E-114	general transcription factor 2-I [Homo sapiens]	-6
324	988665.10	2219234	g2827180	4.00E-19	general transcription factor 2-I; alternative splice product [Homo sapiens]	-6
325	334634.1	3230940	g2224577	0	KIAA0318 [Homo sapiens]	-6
326	2823239CB1	940823	g207409	0	tyrosine hydroxylase (EC 1.14.16.2) [Rattus norvegicus]	-6
327	021413CB1	1629851	g1488413	1.00E-13	N8 gene product=D52 homolog/leucine zipper protein [Homo sapiens]	-6.1
328	637182CB1	3771476	g293689	0	lamin B [Mus musculus]	-6.1
329	1297347CB1	1813133	g437102	3.00E-88	HMG-1 [Mus musculus]	-6.2
330	149914.15	2446238	g505098	1.00E-113	KIAA0069 [Homo sapiens]	-6.2
331	418689CB1	1646294	g51053	0	GATA-3 factor [Mus musculus]	-6.3
332	2232180CB1	039817	g220136	0	thymidylate synthase [Homo sapiens]	-6.4
333	092267CB1	1932189	g16999046	0	Delta 1 [Rattus norvegicus]	-6.9
334	227432.21	617878	g3641300	0	potassium channel [Rattus norvegicus]	-7.1
335	227432.22	617878	g2801452	0	potassium channel; KvEBN1 [Homo sapiens]	-7.1
336	253570.30	1516301	g1778840	0	INS-1 winged helix [Rattus norvegicus]	-7.3
337	253570.32	1516301	g1842255	0	hepatocyte nuclear factor-3/fork head homolog 11B [Homo sapiens]	-7.3
338	3332616CB1	1502188	g1244408	2.00E-17	neuronatin alpha [Homo sapiens]	-7.4
339	1832346CB1	1721744	g339948	0	tropomodulin [Homo sapiens]	-7.4
340	221500.1	1672676	g2130632	0	synaptotagmin XI [Rattus norvegicus]	-7.5
341	1794861CB1	1515980	g557272	0	HYL tyrosine kinase [Homo sapiens]	-7.6
342	202239.1	3812392	g200768	0	ribonucleotide reductase subunit M2 [Mus musculus]	-7.6
343	4181211CB1	661492	g1302658	0	neural cell adhesion molecule L1 [Homo sapiens]	-7.7
344	331051.4	661492	g347807	3.00E-96	cell adhesion molecule L1 [Homo sapiens]	-7.7
345	1454418CB1	1525795	g29839	1.00E-172	CDC2 polypeptide (CDC2) (AA 1-297) [Homo sapiens]	-7.7
346	242309.6	1403636	g882147	0	CRMP-62 [Gallus gallus]	-7.8
347	232888.4	129009	g2668444	0	topoisomerase II [Sus scrofa]	-7.8
348	978190.8	3856893	g976235	0	kinesin family protein KIF1a [Mus musculus]	-7.8
349	2700132CB1	2470485	g1177528	0	Kif-67 [Mus musculus]	-8

PA-0046 US

TABLE 1

SEQ ID NO	Template ID	Clone ID	GenBank Hit	E-value	Annotation	Bal DE
350	343934_1	1267880	g3641671	0	doublecortin [Mus musculus]	-8.3
351	3145862CB1	3176669	g1763259	0	collapsin response mediator 1 [Mus musculus]	-8.3
352	1292191CB1	2821341	g5834566	6.00E-65	chromogranin B (secretogranin 1, SCG1) [Homo sapiens]	-8.3
353	988660_32	1921393	g51442	2.00E-09	putative [Mus musculus]	-9.2
354	2522352CB1	986752	g2506836	0	DNA replication licensing factor MCM7 (CDC47 homolog) [Homo sapiens]	-9.9
355	244622_1	1412749	g4836723	7.00E-90	HMP19 protein [Homo sapiens]	-10.6
356	1555752CB1	3596833	g3192879	0	MAD3-like protein kinase [Homo sapiens]	-10.7
357	2324155CB1	1730052	g292166	1.00E-154	69 kD autoantigen [Homo sapiens]	-11.2
358	1100140_7	2916753	g184236	3.00E-83	high mobility group 2 protein [Homo sapiens]	-13.8
359	1100140_12	2916753	g184236	1.00E-98	high mobility group 2 protein [Homo sapiens]	-13.8
360	3393396CB1	494905	g63099	0	B-myb [Gallus gallus]	-13.8
361	026662_3	485111	g6319178	0	LEK1 [Mus musculus]	-19.2
362	1315515CB1	2821036	g338051	0	secretogranin II [Homo sapiens]	-19.4
363	406387_1	2373263	g5689439	1.00E-161	KIAA1051 protein [Homo sapiens]	-19.8
364	1610121CB1	2820985	g181521	0	aromatic amino acid (dopa) decarboxylase [Homo sapiens]	-21.1
365	330839_1	2811651	g386983	1.00E-164	N-myc [Homo sapiens]	-37.9

PA-0046US

TABLE 2

SEQ ID NO	Template ID	Clone ID	Start	Stop
1	1497123CB1	1497123	300	1261
2	2985802CB1	3553729	6501	7088
3	475532.4	2859033	1	142
4	3138290CB1	1870965	34	5098
5	474310.40	1672744	1418	3957
6	410580.16	1445767	643	2168
7	337518.25	1674454	1234	3035
8	1303785CB1	79576	1100	1335
9	1044033.4	1514989	326	1982
10	1000222.31	690313	969	1529
11	403873.4	2329216	624	1460
12	1383105.12	4049957	136	1158
13	1383354.13	1572533	317	1260
14	697785CB1	2495131	21	332
15	420115CB1	1904751	1420	1958
16	1101453.2	2949427	72	682
17	1399366.20	2055534	4836	5848
18	3072333CB1	1447903	427	2440
19	1270681.1	1804548	1382	2242
20	1505038CB1	1987358	1199	3647
21	1035602.5	1854220	356	804
22	1330167.3	1001730	108	340
23	1003386CB1	1664320	547	1101
24	1097334.1	2483605	132	619
25	959142CB1	2804667	2455	5356
26	1359783CB1	1798209	736	2873
27	063646CB1	557012	544	1852
28	1519595CB1	2056395	938	2657
29	2054176CB1	3142736	660	2545
30	1312325CB1	1319608	2199	2722
31	022404.25	1319608	3805	4401
32	1787335CB1	1958902	726	1992
33	1193648.7	1851696	268	858
34	1193648.1	1851696	6053	6167
35	1867861CB1	1448051	8022	9703
36	5511889CB1	1650238	89	2294
37	3094768CB1	2902903	160	778
38	1256895CB1	1720056	721	2419
39	2019981CB1	1733490	2424	3921
40	2708240CB1	3084122	1730	3549
41	1092427.1	1313183	3747	5208
42	351841.7	1852047	2927	3756
43	022221.43	1314882	8395	10551
44	2190217CB1	78783	207	370
45	410910.3	2518178	2047	4796
46	1966280CB1	1700077	930	1514
47	430669.39	1572555	110	495
48	430669.23	1572555	1213	1596
49	1870753CB1	782235	4047	4691
50	3173735CB1	521139	322	2050
51	1330185.14	2868138	738	1146
52	2314132CB1	3118643	1118	2410
53	2508205CB1	2057296	480	2127
54	3326672CB1	1995380	27	565
55	234202.34	1995380	372	865

PA-0046US

TABLE 2

SEQ ID NO	Template ID	Clone ID	Start	Stop
56	078242CB1	1319020	1743	1880
57	220943.20	417451	2272	2861
58	1383320.13	1558081	1275	3419
59	3526170CB1	2242648	533	1276
60	184081.24	27775	188	424
61	1821331CB1	1394401	525	2809
62	3660006CB1	1720114	2517	4383
63	089172.13	3693273	1727	4633
64	3084563CB1	2852042	87	1804
65	241227.17	1402715	515	1496
66	348151.2	1618422	3955	6433
67	1720808CB1	2606307	668	3615
68	998552.6	459651	663	1847
69	040652.35	2508261	541	981
70	040652.36	2508261	2420	2860
71	082155CB1	522294	542	1439
72	190144CB1	1668794	26	812
73	234537.3	1718651	3060	3637
74	1088425.1	162769	25	1178
75	254547.1	3134070	241	1028
76	2676170CB1	3820761	627	1978
77	1092181.1	2105963	37	514
78	471362.33	1720149	443	926
79	471362.27	1720149	319	771
80	1162416.1	2102320	1	157
81	252151.12	1599344	1054	1635
82	252151.7	1599344	1	579
83	358892.1	2057260	3649	3810
84	1296867CB1	3506985	209	793
85	337518.7	3506985	285	2721
86	1344279CB1	2771046	1591	3649
87	2731776CB1	2057601	1553	2381
88	1090035.1	1994472	40	450
89	1089929.9	2683564	646	778
90	2723092CB1	2633207	793	1058
91	2174489CB1	2173208	2599	3196
92	1253978CB1	1867652	606	2740
93	2274011CB1	1909488	606	1154
94	3119737CB1	2733928	183	414
95	1384695.102	1514318	2903	3243
96	257332CB1	1402228	1435	3048
97	2972880CB1	1636171	1163	1832
98	550425CB1	550425	482	1771
99	014284CB1	1822716	696	1862
100	1091854.7	1708528	4484	8482
101	138709.5	2844989	793	2272
102	375954.1	1404153	1066	3654
103	1262781CB1	3511216	947	1540
104	282761.16	3511216	2458	2924
105	3090708CB1	1283532	849	1996
106	230062.4	1711206	4892	6599
107	483043CB1	1854277	294	756
108	348205.9	1854277	564	977
109	1256295.18	1702350	828	1323
110	875668CB1	1418741	302	747

PA-0046US

TABLE 2

SEQ ID NO	Template ID	Clone ID	Start	Stop
111	1180189.1	2664388	425	958
112	3109992CB1	2483173	5	1537
113	1250434CB1	1711151	2302	2787
114	1327838.1	3721987	39	327
115	2021477CB1	2190284	139	873
116	235171.20	1940994	3600	3851
117	149832CB1	604856	466	1002
118	1759127CB1	1759127	2503	3425
119	2048551CB1	2048551	1	558
120	3282941CB1	155904	993	1501
121	2733135CB1	2806166	523	1903
122	2176269CB1	1405940	790	2462
123	1218607CB1	477045	300	889
124	1553795CB1	1906574	2283	2722
125	238538.22	1906574	1044	1569
126	246546.9	2936505	358	860
127	234223.14	1672442	4807	6314
128	2054053CB1	2054053	332	869
129	1613766CB1	1640161	1176	1567
130	233454.3	1636639	930	1580
131	347699.13	1358285	2709	3065
132	3531583CB1	1358285	2458	3191
133	407096.14	630625	2268	3868
134	482411.26	2304121	29	519
135	482411.25	2304121	1168	1318
136	1258943CB1	434771	1739	3350
137	1327030.1	450574	353	1225
138	025595.22	1962971	4003	5656
139	995174.1	1975129	568	2327
140	1709732CB1	269456	1219	3491
141	1040610.4	692827	557	1390
142	055498.6	1865767	3980	4262
143	181172CB1	2503037	8	1168
144	2705515CB1	1846209	677	2204
145	480228.3	1997250	555	1014
146	360929.39	63038	85	296
147	1989087CB1	1603057	651	1324
148	995068.16	1904994	462	925
149	1217216.1	1976279	12140	12702
150	474426.5	1281473	306	1426
151	350521.22	2078364	1076	1891
152	1075592.6	1686585	3257	4529
153	1485867CB1	1959565	1635	2290
154	2515360CB1	1887959	4110	4667
155	3290944CB1	3598222	2388	3877
156	441206.15	2849603	967	2806
157	1712327CB1	1712327	1675	2673
158	1393778CB1	2056987	5339	5789
159	480127.44	2056987	1037	1246
160	1870941CB1	1870941	686	2204
161	2495110CB1	3176845	568	815
162	034711.3	3425195	2588	3084
163	251776.14	418731	2757	3391
164	239511.5	1821971	3967	5570
165	989878.1	1997703	2259	3042

PA-0046US

TABLE 2

SEQ ID NO	Template ID	Clone ID	Start	Stop
166	1558664CB1	2018222	354	799
167	3602501CB1	3602501	1141	1784
168	5549580CB1	1736926	1057	2249
169	2687977CB1	1526282	23	2808
170	3168062CB1	1662688	520	1064
171	245367.2	3215205	452	2440
172	470587CB1	3940755	1735	2236
173	1631074CB1	64286	1477	1652
174	347829.12	185448	492	2202
175	347699.11	2058242	3889	4665
176	1251672.1	1453450	6281	7539
177	1291022CB1	1291022	1115	2019
178	237405.19	2380381	273	1420
179	2685676CB1	2513883	465	882
180	010672CB1	549196	119	635
181	234630.58	549196	213	788
182	332595.5	3249851	160	733
183	332595.8	3249851	4129	4680
184	335086.1	3602403	3018	3387
185	1342493CB1	1453748	1684	2248
186	232691.20	2505425	554	1692
187	238814.2	1417211	1660	4002
188	201571.1	959745	278	1827
189	199882.5	1449824	4198	5529
190	237487.22	2380042	250	443
191	237487.21	2380042	595	756
192	305557CB1	29564	55	257
193	1378745CB1	147184	979	1422
194	1818836CB1	1818836	34	2284
195	137946.3	690994	5224	6258
196	2110909CB1	2825369	938	2140
197	200578.1	1397926	1163	2312
198	259592CB1	197207	443	751
199	5584521CB1	1965863	131	653
200	399428.7	1491445	1662	2204
201	117509.4	3012290	72	1586
202	3255458CB1	1597330	123	615
203	1430889CB1	1856520	236	669
204	445048.6	1856520	497	923
205	4946593CB1	2852818	1624	2578
206	350605.45	4114209	1448	1913
207	1413644CB1	1413644	782	2021
208	984009.2	1446475	68	808
209	627662CB1	1631511	1128	2113
210	1382932.11	2175008	4209	4703
211	2721850CB1	1624024	1162	2690
212	994902.1	2059691	530	1222
213	442744.17	1610993	1331	1866
214	442744.21	1610993	1571	2138
215	1908920CB1	2134356	755	1192
216	399101.31	2134356	514	1144
217	183198CB1	924319	774	1255
218	1397781.7	1522716	1328	1966
219	899496.9	812141	1463	2552
220	2111330CB1	1975209	1034	1781

PA-0046US

TABLE 2

SEQ ID NO	Template ID	Clone ID	Start	Stop
221	331591.1	2452650	50	429
222	337119.8	2488567	742	1319
223	245011.11	2232471	879	1228
224	1988468CB1	2232471	886	1876
225	331470.8	1457726	3107	3620
226	411388CB1	591358	486	842
227	253450.9	1347232	12543	14884
228	351209.16	3686211	1030	2447
229	2124320CB1	2204916	3	2226
230	903876.1	548019	2801	5026
231	1238339CB1	2108793	179	677
232	245310.36	2108793	900	1367
233	2696735CB1	2696735	72	1519
234	338036.2	1449054	661	1416
235	236484.15	1922533	3229	4192
236	232719.2	537580	2541	3462
237	462249.1	1830083	2469	3616
238	1187408.1	30672	1252	1462
239	627856CB1	1559756	311	829
240	553078CB1	1985104	731	1832
241	048612.15	1975268	2605	2853
242	048612.12	1975268	1114	1662
243	1099779.1	1612306	1043	1732
244	1520855CB1	179929	4384	6269
245	1179282.1	2870970	730	1328
246	2770449CB1	1658320	843	1776
247	1430336CB1	30291	650	805
248	903105.6	544213	4275	4675
249	1327417.14	2211625	1	435
250	1327417.10	2211625	405	995
251	230712.24	2814551	407	940
252	982520.1	2986240	18	3113
253	311807CB1	821141	641	1853
254	1479370CB1	1626460	2350	3565
255	2993696CB1	2884613	13	2488
256	4004223CB1	1810945	425	955
257	453835.19	1723035	4103	5200
258	391741.16	1634279	1823	2346
259	391741.64	1634279	2996	3441
260	1382958.26	3876715	591	902
261	232567.4	1577614	511	1140
262	1720770CB1	2189762	323	811
263	253987.19	700559	493	1406
264	2047630CB1	1381654	815	1897
265	238203.11	999864	4229	5092
266	899410.5	1724967	4019	4432
267	474311.3	2736056	3931	6660
268	2169835CB1	1003486	1792	2109
269	290021.11	1003486	2586	3038
270	267324CB1	2132217	1179	1454
271	2119372CB1	1889060	1770	3137
272	2818482CB1	2668334	404	1219
273	1330231.11	2594308	333	1159
274	1330117.5	692201	649	1299
275	233402.3	2056290	5739	6369

PA-0046US

TABLE 2

SEQ ID NO	Template ID	Clone ID	Start	Stop
276	1622313CB1	1901061	1640	2538
277	2939887CB1	1375115	2059	2667
278	1804120CB1	1901095	2380	2963
279	245485.12	1901095	630	1083
280	1285395CB1	15834	1238	1533
281	036391.3	399035	1109	1635
282	036391.13	399035	2283	2683
283	474435.16	1610523	1326	2035
284	2495292CB1	2495292	1974	3637
285	251651.4	1645766	881	1434
286	5408483CB1	3493061	489	3217
287	347876.6	103669	290	2962
288	1289007CB1	1986737	942	1758
289	233301.18	814216	2032	2585
290	2157771CB1	2825656	5088	5612
291	2958028CB1	1569804	1259	1854
292	233811.8	1569804	316	734
293	1270302CB1	1486358	1376	2197
294	067163CB1	1384823	66	639
295	002387CB1	2781405	884	1288
296	2798854CB1	4385292	1174	3091
297	1292280CB1	3496395	1271	1842
298	979248.2	3496395	1	192
299	236240.3	1850531	472	1929
300	234427.4	1616315	911	1423
301	234427.7	1616315	1	625
302	411205.16	160410	195	679
303	411205.5	160410	1903	3093
304	238854.23	1369473	913	1296
305	405008.1	726201	69	488
306	372981.9	1576329	62	417
307	345125.8	180439	552	1110
308	345125.17	180439	270	840
309	1723834CB1	1723834	2901	3240
310	407588.2	1640108	1458	1771
311	1970111CB1	1970111	1059	2805
312	058208CB1	467621	609	1459
313	333461.2	4003342	1538	2064
314	002940CB1	161207	86	1222
315	365153CB1	2375329	509	1794
316	034181CB1	1316528	1946	3633
317	264633.20	1709017	1	562
318	264633.19	1709017	2523	3069
319	1760566CB1	2657680	536	798
320	3296553CB1	1739904	2395	2868
321	199471.2	2414624	125	1463
322	1558165CB1	1403041	431	1842
323	988665.6	2219234	878	1327
324	988665.10	2219234	276	797
325	334634.1	3230940	3713	5552
326	2823239CB1	940823	1174	1778
327	021413CB1	1629861	210	1669
328	637182CB1	3771476	1110	1582
329	1297347CB1	1813133	275	1067
330	149914.15	2446238	412	2382

PA-0046US

TABLE 2

SEQ ID NO	Template ID	Clone ID	Start	Stop
331	418689CB1	1646294	1618	2260
332	2232180CB1	39817	798	963
333	092267CB1	1932189	805	1262
334	227432.21	617878	447	1001
335	227432.22	617878	843	1376
336	253570.30	1516301	2588	3043
337	253570.32	1516301	2747	3519
338	3332616CB1	1502188	15	547
339	1832346CB1	1721744	1109	2734
340	221500.1	1672676	3901	5215
341	1794861CB1	1515980	779	1949
342	202239.1	3812392	0	1680
343	4181211CB1	661492	2001	2372
344	331051.4	661492	1175	1676
345	1454418CB1	1525795	336	1776
346	242309.6	1403636	3247	3729
347	232888.4	129009	3843	5647
348	978190.8	3856893	10	991
349	2700132CB1	2470485	412	985
350	343934.1	1267860	8048	9390
351	3145862CB1	3176609	1646	2820
352	1292191CB1	2821341	9	2541
353	988660.32	1921393	284	703
354	2522352CB1	986752	443	2551
355	244622.1	1412749	1845	2383
356	1555752CB1	3596853	27	3642
357	2324155CB1	1730052	112	1683
358	1100140.7	2916753	1	542
359	1100140.12	2916753	575	1152
360	3393396CB1	494905	166	2601
361	026662.3	485111	7806	10241
362	1315515CB1	2821036	31	2342
363	406387.1	2373263	5566	6690
364	1610121CB1	2820985	517	1895
365	330839.1	2811651	1054	2499